<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64370</article-id><article-id pub-id-type="doi">10.7554/eLife.64370</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>SATB2 induction of a neural crest mesenchyme-like program drives melanoma invasion and drug resistance</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-212749"><name><surname>Fazio</surname><given-names>Maurizio</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0083-6601</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-213412"><name><surname>van Rooijen</surname><given-names>Ellen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-213414"><name><surname>Dang</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-213415"><name><surname>van de Hoek</surname><given-names>Glenn</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-213418"><name><surname>Ablain</surname><given-names>Julien</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-213413"><name><surname>Mito</surname><given-names>Jeffrey K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-89732"><name><surname>Yang</surname><given-names>Song</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-213416"><name><surname>Thomas</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82758"><name><surname>Michael</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-213419"><name><surname>Fabo</surname><given-names>Tania</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8987-0672</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-213420"><name><surname>Modhurima</surname><given-names>Rodsy</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-213417"><name><surname>Pessina</surname><given-names>Patrizia</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82751"><name><surname>Kaufman</surname><given-names>Charles K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3122-1677</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82753"><name><surname>Zhou</surname><given-names>Yi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20435"><name><surname>White</surname><given-names>Richard M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9099-9169</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-3910"><name><surname>Zon</surname><given-names>Leonard I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0860-926X</contrib-id><email>zon@enders.tch.harvard.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution>Howard Hughes Medical Institute, Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Brigham and Women’s Hospital, Department of Pathology</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Stem Cell Program and the Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Division of Medical Oncology, Department of Medicine, Washington University in Saint Louis</institution><addr-line><named-content content-type="city">Saint Louis</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Developmental Biology, Washington University in Saint Louis</institution><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Memorial Sloan Kettering Cancer Center and Weill-Cornell Medical College</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>McArthur</surname><given-names>Grant</given-names></name><role>Reviewing Editor</role><aff><institution>Peter MacCallum Cancer Centre</institution><country>Australia</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Bronner</surname><given-names>Marianne E</given-names></name><role>Senior Editor</role><aff><institution>California Institute of Technology</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>02</day><month>02</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e64370</elocation-id><history><date date-type="received" iso-8601-date="2020-10-27"><day>27</day><month>10</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-02-01"><day>01</day><month>02</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Fazio et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Fazio et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-64370-v2.pdf"/><abstract><p>Recent genomic and scRNA-seq analyses of melanoma demonstrated a lack of recurrent genetic drivers of metastasis, while identifying common transcriptional states correlating with invasion or drug resistance. To test whether transcriptional adaptation can drive melanoma progression, we made use of a zebrafish mitfa:<italic>BRAFV600E</italic>;<italic>tp53-/-</italic> model, in which malignant progression is characterized by minimal genetic evolution. We undertook an overexpression-screen of 80 epigenetic/transcriptional regulators and found neural crest-mesenchyme developmental regulator SATB2 to accelerate aggressive melanoma development. Its overexpression induces invadopodia formation and invasion in zebrafish tumors and human melanoma cell lines. SATB2 binds and activates neural crest-regulators, including <italic>pdgfab</italic> and <italic>snai2</italic>. The transcriptional program induced by SATB2 overlaps with known MITF<sup>low</sup>AXL<sup>high</sup> and AQP1<sup>+</sup>NGFR1<sup>high</sup> drug-resistant states and functionally drives enhanced tumor propagation and resistance to Vemurafenib in vivo. In summary, we show that melanoma transcriptional rewiring by SATB2 to a neural crest mesenchyme-like program can drive invasion and drug resistance in autochthonous tumors.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>melanoma</kwd><kwd>SATB2</kwd><kwd>metastasis</kwd><kwd>neural crest</kwd><kwd>drug resistance</kwd><kwd>epigenetics</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Boehringer Ingelheim Fonds</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Fazio</surname><given-names>Maurizio</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003246</institution-id><institution>Netherlands Organisation for Scientific Research</institution></institution-wrap></funding-source><award-id>Rubico Fellowship</award-id><principal-award-recipient><name><surname>van Rooijen</surname><given-names>Ellen</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004622</institution-id><institution>Dutch Cancer Society</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>van Rooijen</surname><given-names>Ellen</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01 CA103846</award-id><principal-award-recipient><name><surname>Zon</surname><given-names>Leonard I</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005190</institution-id><institution>Melanoma Research Alliance</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Zon</surname><given-names>Leonard I</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009784</institution-id><institution>Starr Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>White</surname><given-names>Richard M</given-names></name><name><surname>Zon</surname><given-names>Leonard I</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000863</institution-id><institution>Ellison Medical Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Zon</surname><given-names>Leonard I</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A genetic discovery screen for epigenetic factors accelerating melanoma development in vivo identifies SATB2 as a driver of tumor invasion and resistance to FDA-approved BRAF-targeted inhibitor Vemurafenib.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Both sequencing of patient precursor lesions (<xref ref-type="bibr" rid="bib76">Shain et al., 2015</xref>) and modeling in transgenic animals (<xref ref-type="bibr" rid="bib68">Pérez-Guijarro et al., 2017</xref>; <xref ref-type="bibr" rid="bib87">van Rooijen et al., 2017</xref>) showed that acquisition of oncogenic <italic>BRAF</italic> or <italic>NRAS</italic> mutations alone is insufficient to drive melanoma initiation. Reconstruction of the clonal history of advanced human melanoma suggests that few driver mutations, including loss of tumor suppressors, are acquired in early transformed melanocytes, and that high mutational burden and genomic instability are later events in malignant progression (<xref ref-type="bibr" rid="bib8">Birkeland et al., 2018</xref>; <xref ref-type="bibr" rid="bib16">Ding et al., 2014</xref>). Recently, a pan-cancer whole-genome analysis of metastatic solid tumors, including 248 melanoma patients, showed a surprisingly high degree of similarity in mutational landscape and driver genes between metastatic tumors and their respective primaries, as well as across multiple metastatic lesions within the same patient (<xref ref-type="bibr" rid="bib69">Priestley et al., 2019</xref>). The lack of recurrently mutated genes in metastasis, and the limited genetic diversity across metastatic sites suggests that genetic selection of mutated drivers is unlikely to be responsible for metastatic progression. Meanwhile, despite the high degree of mutational burden and genetic intra- and inter-patient heterogeneity observed in melanoma, several bulk RNA-seq and scRNA-seq analyses of metastatic melanoma patient samples have identified common recurrent transcriptional states correlating with invasion (mesenchymal signature; <xref ref-type="bibr" rid="bib89">Verfaillie et al., 2015</xref>), drug resistance (MITF<sup>low</sup>/AXL<sup>high</sup>; <xref ref-type="bibr" rid="bib84">Tirosh et al., 2016</xref>), a neural crest-like state correlating with minimal residual disease persistence during targeted therapy with MAPK inhibitors (MITF<sup>low</sup>/NGFR1<sup>high</sup>/AQP1<sup>high</sup>; <xref ref-type="bibr" rid="bib72">Rambow et al., 2018</xref>), and even response to immunotherapy (NGFR1<sup>high</sup>; <xref ref-type="bibr" rid="bib9">Boshuizen et al., 2020</xref>). Yet, the existing literature on these often less proliferative cell states (<xref ref-type="bibr" rid="bib72">Rambow et al., 2018</xref>) has been either descriptive (<xref ref-type="bibr" rid="bib84">Tirosh et al., 2016</xref>), limited to in vitro perturbations, or relied on transplant models (<xref ref-type="bibr" rid="bib72">Rambow et al., 2018</xref>; <xref ref-type="bibr" rid="bib9">Boshuizen et al., 2020</xref>), and as such their role in oncogenesis outside of iatrogenic drug treatment remains less clear.</p><p>Using a zebrafish transgenic melanoma model, we have previously shown that in a cancerized field of melanocytes carrying driving oncogenic mutations, such as <italic>BRAF<sup>V600E</sup></italic> and loss of <italic>tp53,</italic> only a few cells or subclones will go on to develop a malignant tumor, and that this event is marked by re-expression of developmental neural crest (NC)markers <italic>sox10</italic> and <italic>crestin</italic> (<xref ref-type="bibr" rid="bib40">Kaufman et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">McConnell et al., 2019</xref>). Similar to the observation in human metastatic patient samples, malignant progression from transformed melanocytes in experimental animal models is not explained by the very limited genetic evolution observed in these tumors (<xref ref-type="bibr" rid="bib95">Yen et al., 2013</xref>). Taken together, these observations in human patients and animal disease models raise the question whether epigenetic adaptation, rather than genetic selection, can contribute to tumor progression by altering the transcriptional state of the tumor.</p><p>Here, we address this hypothesis by high-throughput genetic perturbation of 80 epigenetic/transcriptional regulators in autochthonous primary tumors, by leveraging a transgenic zebrafish melanoma model uniquely suited to precisely and rapidly perturbate tumor development in vivo (<xref ref-type="bibr" rid="bib12">Ceol et al., 2011</xref>), at a scale and speed much greater than possible with genetically engineered murine melanoma models. We identify Special AT-rich Binding protein 2 (SATB2) as a novel accelerator of melanoma onset driving an aggressive phenotype in primary tumors suggestive of metastatic spreading. SATB2 acts as a transcriptional regulator by recruiting members of the acetyl transferase and histone demethylase complexes to target genes and altering the local chromatin organization and activation state (<xref ref-type="bibr" rid="bib101">Zhou et al., 2012</xref>). Its expression has been shown to correlate with patient outcome in several tumor types (<xref ref-type="bibr" rid="bib60">Naik and Galande, 2019</xref>; <xref ref-type="bibr" rid="bib97">Yu et al., 2017b</xref>). In different tissues and tumor types, SATB2 has been shown to play a role in oncogenic transformation and proliferation, or epithelial-to-mesenchymal transition (EMT), migration, and self-renewal (<xref ref-type="bibr" rid="bib22">Gan et al., 2017</xref>; <xref ref-type="bibr" rid="bib60">Naik and Galande, 2019</xref>; <xref ref-type="bibr" rid="bib62">Nayak et al., 2019</xref>; <xref ref-type="bibr" rid="bib90">Wang et al., 2019</xref>; <xref ref-type="bibr" rid="bib93">Wu et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Xu et al., 2017</xref>; <xref ref-type="bibr" rid="bib96">Yu et al., 2017a</xref>). SATB2 is a transcription factor and chromatin remodeler with a well-conserved structure and expression pattern across chicken, mouse, and zebrafish during the development and migration of the cranial neural crest (CNC) and neuronal development. It is required for the development of the exo-mesenchymal lineages of the CNC (<xref ref-type="bibr" rid="bib77">Sheehan-Rooney et al., 2010</xref>; <xref ref-type="bibr" rid="bib78">Sheehan-Rooney et al., 2013</xref>), and neuronal axon formation (<xref ref-type="bibr" rid="bib55">McKenna et al., 2015</xref>; <xref ref-type="bibr" rid="bib79">Shinmyo and Kawasaki, 2017</xref>). In facts, SATB2 inactivating mutations in humans have been associated with cleft palate, intellectual disability, facial dysmorphism, and development of odontomas, defining a neurocristopathy referred to as SATB2-associated syndrome (<xref ref-type="bibr" rid="bib41">Kikuiri et al., 2018</xref>; <xref ref-type="bibr" rid="bib98">Zarate et al., 2019</xref>; <xref ref-type="bibr" rid="bib99">Zarate and Fish, 2017</xref>). Through a combination of zebrafish in vivo allotransplants and validation in human melanoma cell lines, we show that SATB2 drives enhanced invasion via invadopodia formation and an EMT-like phenotype. Mechanistically, chromatin and transcriptional characterization of primary zebrafish SATB2 tumors vs. EGFP controls via ChIP-seq and RNA-seq shows SATB2 to bind and induce transcriptional activation of neural crest regulators, including <italic>snai2</italic> and <italic>pdgfab</italic>. The transcriptional program induced by SATB2 overexpression is conserved between zebrafish and human melanoma, and overlaps with the aforementioned MITF<sup>low</sup>/AXL<sup>high</sup> (<xref ref-type="bibr" rid="bib84">Tirosh et al., 2016</xref>) and neural crest-like MITF<sup>low</sup>/NGFR1<sup>high/</sup>AQP1<sup>high</sup> drug-resistant states (<xref ref-type="bibr" rid="bib72">Rambow et al., 2018</xref>). Finally, we show SATB2 transcriptional rewiring to functionally drive enhanced tumor propagation and resistance to MAPK inhibition by Vemurafenib in zebrafish tumor allografts in vivo.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>In vivo overexpression screen of epigenetic factors identifies SATB2 as melanoma accelerator</title><p>To interrogate whether epigenetic reprogramming can accelerate melanoma development, we utilized a genetic discovery driven approach and undertook an in vivo overexpression screen. We tested 80 chromatin factors: 15 pools of 5 factors, and 6 additional single factors including previously published positive controls SETDB1, SUV39H1 (<xref ref-type="bibr" rid="bib12">Ceol et al., 2011</xref>) (see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). EGFP was used as a negative control, and we tested CCND1 as an additional positive control (known driver often amplified in melanoma [<xref ref-type="bibr" rid="bib11">Cancer Genome Atlas Network, 2015</xref>]). As a screening platform, we leveraged a zebrafish melanoma model driven by tissue-specific expression of human oncogenic <italic>BRAF<sup>V600E</sup></italic> in a <italic>tp53</italic> and <italic>mitfa</italic>-deficient background (<xref ref-type="bibr" rid="bib12">Ceol et al., 2011</xref>). Tg(<italic>mitfa:BRAF<sup>V600E</sup>); tp53-/-; mitfa-/-</italic> zebrafish lack melanocytes and do not develop melanoma. Mosaic integration of the transposon-based expression vector MiniCoopR (MCR), rescues melanocyte development by restoring <italic>mitfa,</italic> while simultaneously driving tissue-specific expression of candidate genes (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Thus, in mosaic F0 transgenics all melanocytes express the candidate gene tested (described in <xref ref-type="bibr" rid="bib12">Ceol et al., 2011</xref>). We identified six significant candidate accelerator pools (Pool B,D,F,G,I,L vs. MCR:EGFP Log-rank (Mantel-Cox) test p&lt;0.0001****) of which Pool F had the strongest acceleration (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), and tested individual factors from four accelerating pools (B/F/G/I) and a non-significant pool (C) (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–D</xref>). Single factor validation of Pool F (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) showed that SATB2-overexpression (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A–B</xref>) is sufficient to strongly accelerate melanoma development (median onset of 12 weeks, compared to 21.4 weeks for MCR:EGFP, Log-rank (Mantel-Cox) test p&lt;0.0001****) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Single factor validation of additional pools (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–D</xref>) identified additional genes, with a significant but milder acceleration of melanoma onset (TRIM28, median onset 18.7 weeks, n = 72; CDYL2, median onset 18.4 weeks, n = 72; DMAP1, median onset 18 weeks, n = 98; CBX5, median onset 19.1 weeks, n = 51; and PYGO2, median onset 19.7 weeks, n = 77), and CBX3 (median onset not reached,~20% of animals show tumors at 20 weeks, n = 55) to delay melanoma onset (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). MCR:SATB2 tumors appear grossly aggressive (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>, <xref ref-type="video" rid="video1">Video 1</xref>), are invasive, and melanoma cells are frequently observed in internal organs and spreading along the spinal cord, while organ involvement is rarely observed in MCR:EGFP (<xref ref-type="fig" rid="fig1">Figure 1E–G</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C–F</xref>). We thus focused on further characterizing SATB2’s phenotype and investigating its mechanism of action. SATB2 effect on melanoma development is <italic>BRAFV600E</italic> and <italic>tp53-/-</italic>dependent (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>). Melanocyte-specific expression of Cas9 and of a gRNA efficiently targeting zebrafish <italic>satb2</italic> (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B</xref>) using the established MCR:CRISPR system (<xref ref-type="bibr" rid="bib2">Ablain et al., 2018</xref>) did not affect tumor onset compared to control targeting <italic>tp53</italic> (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3C</xref>). While we did not verify <italic>satb2</italic> expression in transgenic tumors, this data suggest it to likely be dispensable for melanoma initiation. Furthermore, SATB2 closely related gene SATB1 did not affect tumor development (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3D</xref>). The acceleration phenotype is not due to increased cellular proliferation, since SATB2-overexpression in primary zebrafish tumors (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A</xref>) or in a panel of human melanoma cell lines via a TETon tetracycline inducible lentiviral vector (here referred to as iSATB2) did not result in increased proliferation (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B,C</xref>). Our data demonstrate that SATB2-overexpression accelerates melanoma malignant progression without affecting proliferation, but SATB2 is not sufficient and unlikely to be required for melanoma initiation.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Overexpression screen of epigenetic regulators identifies SATB2 as an accelerator of melanoma formation in zebrafish.</title><p>(<bold>A</bold>) Schematic overview of screening strategy: MCR expression vector-based reintroduction of the melanocyte master transcription factor <italic>mitfa,</italic> rescues melanocytes and melanoma development. All rescued melanocytes in F0 microinjected embryos also express a candidate human factor. (<bold>B</bold>) Kaplan-Meier melanoma-free survival curves of pooled chromatin factor screen. Six pools were significant [Log-rank (Mantel-Cox) test p&lt;0.0001****]. Pool F (red) had the strongest acceleration effect (Median onset 14 weeks). (<bold>C</bold>) Single factor validation of pool F identifies SATB2 to induce accelerated melanoma onset [Median onset 12 weeks, Log-rank (Mantel-Cox) test, p&lt;0.0001****]. (<bold>D</bold>) Zebrafish MCR:SATB2 tumors are aggressive compared to an MCR:EGFP age-matched control. (<bold>E</bold>) Histopathological analysis revealed that MCR:SATB2 tumors are highly invasive, here shown to invade through the spinal cord, vertebrae, and kidney. (<bold>F</bold>) Isolated melanoma cell clusters were found in the liver, and (<bold>G</bold>) frequent organ involvement is observed in MCR:SATB2 compared to MCR:EGFP controls.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Kaplan-Meier melanoma-free survival curves input files in weeks showing (1 = tumor, 0 = no tumor/censored, no value = lost at follow up).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64370-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Single factor validation of additional pools.</title><p>Kaplan-Meier melanoma-free survival curves of single factor validation of non-significant pool C (<bold>A</bold>) and significantly accelerating pool G (<bold>B</bold>), pool I (<bold>C</bold>), and pool B (<bold>D</bold>) from <xref ref-type="fig" rid="fig1">Figure 1B</xref>. MCR:EGFP (green), MCR:SATB2 (red), and the respective pool (orange) are plotted as controls in each panel. Log-rank (Mantel-Cox) test p values for significant individual genes in the pool vs. MCR:EGFP control are shown (n.s.; not significant). SMARCAL1 and PCAF follow up ended at 13 weeks.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Kaplan-Meier melanoma-free survival curves input files in weeks showing (1 = tumor, 0 = no tumor/censored, no value = lost at follow up).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64370-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>SATB2 overexpression leads to invasive melanoma with organ involvement.</title><p>(<bold>A</bold>) Western blot and (<bold>B</bold>) immunofluorescence validation of human SATB2 protein expression in MCR:SATB2 zebrafish primary tumors. (<bold>C</bold>) Cross-section through zebrafish mounted in a paraffin block. Compared to the MCR:EGFP-injected zebrafish which has a pigmented tumor with confined borders, in the MCR:SATB2-injected zebrafish dispersed pigmented tumor cells can be observed throughout the body. MCR:SATB2-injected zebrafish have increase organ involvement, as shown by pigmented melanoma cells (white arrow) in the (<bold>D</bold>) intestine, and (<bold>E</bold>) pancreas. (<bold>F</bold>) Histological aspect of MCR:SATB2 tumors illustrating spindle morphology of melanoma cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>SATB2 is not sufficient and unlikley necessary for melanoma initiation in zebrafish.</title><p>(<bold>A</bold>) Kaplan-Meier survival curves showing that MCR:SATB2 acceleration is dependent on <italic>BRAF<sup>V600E</sup></italic> and <italic>p53<sup>-/-</sup>.</italic> Plotted: MCR:EGFP (n = 44) and MCR:SATB2 (n = 98) into Tg(<italic>mitfa:BRAF<sup>V600E</sup></italic>); <italic>p53<sup>-/-</sup>; mitfa<sup>-/<bold>-</bold></sup></italic>, compared to MCR:SATB2 into <italic>BRAF</italic><sup>-/-</sup>; <italic>p53</italic><sup>-/-</sup> (n = 44) and MCR:SATB2 into <italic>BRAF<sup>+/+</sup>; p53<sup>+/+</sup></italic> (n = 49). Log-rank (Mantel-Cox) test p values are shown. (<bold>B</bold>) T7E1 mutagenesis assay at the CRISPR target site in the <italic>satb2</italic> gene. The assay was performed on genomic DNA from 2 dpf embryos injected at the one-cell stage with <italic>Cas9</italic> mRNA and either a control gRNA (left) or a gRNA against <italic>satb2</italic> (right). Cleavage bands (arrowheads, expected sizes 167 and 303 bp) indicate efficient mutagenesis at the target site. (<bold>C</bold>) Kaplan-Meier survival curves for <italic>p53</italic> CRISPR (n-46), <italic>satb2</italic> CRISPR-1 (n = 74), <italic>satb2</italic> CRISPR-2 (n = 76) injected into [Tg(<italic>mitfa:BRAF<sup>V600E</sup></italic>); <italic>p53<sup>-/-</sup>; mitfa<sup>-/-</sup></italic>] suggest <italic>satb2</italic> to likely be dispensable for melanoma initiation. Log-rank (Mantel-Cox) test, NS; not significant, ****p&lt;0.0001. (<bold>D</bold>) Kaplan-Meier survival curves for MCR:SATB2 (n = 98), MCR:SATB1 (n = 107), and MCR:EGFP (n = 44) into Tg(<italic>mitfa:BRAF<sup>V600E</sup></italic>); <italic>p53<sup>-/-</sup>; mitfa<sup>-/<bold>-</bold></sup></italic> showing that unlike SATB2, closely related gene SATB1 does not accelerate melanoma onset. Log-rank (Mantel-Cox) test, NS; not significant, ****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>SATB2 overexpression does not affect proliferation.</title><p>(<bold>A</bold>) Proliferation rates in primary MCR:EGFP (n = 17) and MCR:SATB2 (n = 16) tumors are not statistically different (unpaired two-tailed <italic>t</italic>-test,), as determined by PH3 immunohistochemistry. (<bold>B</bold>) Western blot for SATB2 after DOX-induction in SKMEL2, SKMEL28 and A375 human melanoma cell lines. β-Actin was used as a loading control. The two lower bands in SKMEL2 and SKMEL28 are likely degradation products of SATB2 due to the overexpression. (<bold>C</bold>) Induction of SATB2 does not affect proliferation rates between parental and transduced cell lines, as determined by CellTiterGLO (NS; not significant).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig1-figsupp4-v2.tif"/></fig></fig-group><media id="video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-64370-video1.mp4"><label>Video 1.</label><caption><title>Zebrafish MCR:EGFP (unpigmented) and MCR:SATB2 (pigmented) melanoma phenotype.</title></caption></media></sec><sec id="s2-2"><title>SATB2 overexpression leads to invadopodia formation and increases migration and invasion in vitro and in vivo</title><p>Given the lack of proliferation changes, we next asked whether SATB2’s aggressive tumor phenotype and internal tumors might be explained by an increase in tumor migration and/or invasion. Using primary zebrafish melanoma in vitro cell cultures, we performed scratch migration assays, that confirmed a heightened migration potential of 3 independent MCR:SATB2 cell lines compared to three independent MCR:EGFP cell lines (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Cytoskeletal staining of zebrafish melanoma in vitro cultures (Zmel1 MCR:EGFP and 45–3 MCR:SATB2) with phalloidin revealed the presence of strong F-actin-positive foci in MCR:SATB2 cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), reminiscent of invadopodia. Invadopodia are cell protrusions involved in metastatic spreading by facilitating anchorage of cells to, and local degradation of the ECM (<xref ref-type="bibr" rid="bib59">Murphy and Courtneidge, 2011</xref>), and are known to be regulated by the PDGF-SRC pathway and EMT. During normal development, invadopodia-like physiologically equivalent structures called podosomes are utilized by neural crest cells to migrate (<xref ref-type="bibr" rid="bib59">Murphy and Courtneidge, 2011</xref>; <xref ref-type="bibr" rid="bib58">Murphy et al., 2011</xref>). Co-localization of F-actin with invadopodium structural component Cortactin in MCR:SATB2 melanoma cell lines confirmed these foci to be invadopodia (<xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Much like in vitro cultures, primary MCR:SATB2 tumors also showed abundant Cortactin expression compared to MCR:EGFP (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Proteolytic activity of invadopodia induces local degradation of the extracellular matrix. To test whether SATB2-expressing cells form functional invadopodia, we plated cells onto Oregon green 488-conjungated gelatin-coated coverslips and assayed for matrix degradation 24–25 hr post-seeding (<xref ref-type="bibr" rid="bib52">Martin et al., 2012</xref>). MCR:SATB2 melanoma cell lines strongly degraded the gelatin matrix, with 49.2–57.9% of cells having degraded gelatin, compared to 5.4% of MCR:Empty control cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C–D</xref>). To validate the effect of SATB2 as a regulator of invadopodia formation in human melanoma, we utilized the panel of iSATB2 human melanoma cell lines. Upon SATB2 induction (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B</xref>), all human melanoma cell lines robustly formed invadopodia and showed significantly increased matrix degradation (<xref ref-type="fig" rid="fig2">Figure 2D–E</xref>, <xref ref-type="video" rid="video2">Video 2</xref>). In SKMEL2, a 10-fold induction of cells with matrix degradation was observed, from a baseline of 5.4 ± 4.5% (SD) of cells with matrix degradation to 58.2 ± 13.2% (SD) of cells after doxycycline treatment (<xref ref-type="fig" rid="fig2">Figure 2D–E</xref>), with evidence of F-actin and Cortactin co-localization in punctae below the cell nucleus, characteristic of invadopodia (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>SATB2 leads to invadopodia formation and increased migration potential in vitro and in vivo.</title><p>(<bold>A</bold>) Phalloidin staining for F-Actin in primary zebrafish melanoma cell culture, reveals the presence of F-actin-positive foci in MCR:SATB2 (45–3) cells, which are not present in MCR:EGFP (zmel1) cells. Scale bar is 20 μm. Primary tumor immunohistochemistry shows MCR:SATB2 tumors abundantly express Cortactin. Scale bar 50 μm. (<bold>B</bold>) MCR:SATB2 (63–4) cells show increased Oregon green 488-conjungated gelatin degradation, compared to MCR (CK5) cells 24–25 hr post-seeding. Scale bar is 50 μm. (<bold>C</bold>) Percentage of cells with degraded gelatin after SATB2 induction in iSATB2 human melanoma cell lines A375, SKMEL2, and SKMEL28 transduced with pInducer20-SATB2. Cells were seeded on gelatin in media +/- doxycycline after 48 hr +/- doxycycline induction. (<bold>D</bold>) Upon SATB2 induction in human melanoma cell line SKMEL2, cells form invadopodia and show increased matrix degradation Scale bar is 20 μm. (<bold>E</bold>) Orthotropic allograft migration assay in transparent <italic>Casper</italic> zebrafish. A total of 300,000 primary pigmented primary melanoma cells were transplanted into the dorsum of irradiated <italic>Casper</italic> recipients, which are monitored for the formation of pigmented distant metastasis that have spread past the anatomical midline. Metastases are represented as black circles. (<bold>F</bold>) Pooled recipient data at the experimental end point at 3.5 weeks post-transplantation, 59.4 ± 2.3% (SEM; n = 76 total recipients, grafted from seven individual donor tumors) of MCR:SATB2 transplants formed distant metastasis, compared to 21.8±4.5% (SEM; n = 37 total recipients grafted from five individual donor tumors) of EGFP-control transplants (p&lt;0.0001). MCR:EGFP transplants developed an average 1.1 ± 0.4 (SD) distant metastasis per fish, versus 4 ± 4.2 (SD) in MCR:SATB2, where a maximum of 20 metastases per fish was observed. (<bold>G</bold>) MCR:SATB2 recipients more frequently developed bilateral (28.9%), and internal metastases (22.4%) compared to MCR:EGFP donors (5.4%), showing spreading along the neural tube (14.5% versus 2.7%). (<bold>H</bold>) At 3.5 weeks-post transplantation, compared to MCR:EGFP donor transplants, MCR:SATB2 transplants develop distant and internal metastases. Histopathology of MCR:SATB2 <italic>Casper</italic> recipients showing a (<bold>I–I</bold>) hypodermal metastasis, and (<bold>I–II</bold>) internal metastasis with spreading along neural tube.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>SATB2 overexpression induces EMT, increased migration and invadopodia formation in zebrafish melanoma.</title><p>(<bold>A</bold>) Scratch assays on cultured MCR tumors show increased migration in MCR:SATB2 tumors. (<bold>B</bold>) Confocal analysis of immunohistochemistry of cultured MCR:SATB2 tumor shows co-localization of Cortactin (green) and F-actin (phalloidin, red), suggesting the formation of invadopodia. DAPI nuclear stain is shown in blue. (<bold>C</bold>) MCR:SATB2 (45–3) cells show increased Oregon green 488-conjungated gelatin degradation 24–25 hr post-seeding. Scale bar is 50 μm. (<bold>D</bold>) Percentage of zebrafish melanoma cells (<bold>n</bold>) with degraded 488-conjungated gelatin 24 hr post-seeding, observed in MCR (CK5, n = 93), MCR:SATB2 (45–3, n = 126), and MCR:SATB2 (63–4, n = 311) cell lines. (<bold>E</bold>) Immunofluorescence showing colocalization of F-actin and Cortactin in SKMEL2 overexpressing SATB2 in the presence of doxycycline (48 hr induction).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>MCR:SATB2 primary tumors and long-term cultures have increase invasion potential in vivo.</title><p>(<bold>A</bold>) Western blot of SATB2 showing retained expression in long term in vitro cultures derived from MCR:SATB2 tumors. Actin loading control is shown. (<bold>B</bold>) Overall survival and (<bold>C</bold>) histology of irradiated <italic>Casper</italic> recipients transplanted with MCR:EGFP Zmel1 (n = 31) or MCR:SATB2 45–3 (n = 31) zebrafish long term in vitro cultures. (<bold>D</bold>) Weekly prospective imaging of primary MCR:SATB2 individual tumor donor allograft in irradiated <italic>Casper</italic> recipient. Arrows indicate distant metastasis from injection site. Related to <xref ref-type="fig" rid="fig2">Figure 2H</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Analysis of SATB2 expression, amplification, and correlation with survival in human melanoma.</title><p>(<bold>A</bold>) Analysis of SATB2 expression across tumor types in TCGA PanCancer dataset using cBio portal (<xref ref-type="bibr" rid="bib23">Gao et al., 2013</xref>). Melanoma (highlighted in red) SATB2 mRNA levels are comparable to other solid tumors where SATB2 has been established to play a role (i.e. RCC, Sarcoma, CRC). (<bold>B</bold>) Western blot of SATB2 and SATB1 with a panel of antibodies showing protein expression in a panel of human melanoma cell lines and zebrafish MCR:EGFP, MCR:SATB2, and MCR:SATB1 control tumors. Actin loading control is shown. (<bold>C</bold>) Frequency of SATB2 amplification in red across multiple available melanoma genomic studies (<xref ref-type="bibr" rid="bib35">ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020</xref>; <xref ref-type="bibr" rid="bib32">Hugo et al., 2015</xref>; <xref ref-type="bibr" rid="bib81">Snyder et al., 2014</xref>; <xref ref-type="bibr" rid="bib85">Van Allen et al., 2014</xref>). (<bold>D</bold>) Correlation between SATB2 expression and melanoma metastasis-related overall survival in two independent publicly available dataset (GSE8401 and GSE22153) of melanoma followed for metastatic progression risk. Continuous expression Z-score optimized plots (mRNA expression Z-score value separating high vs. low expression that results in maximal statistical separation of the two curves) from the default output of the TIDE Harvard Portal gene query <ext-link ext-link-type="uri" xlink:href="http://tide.dfci.harvard.edu/">http://tide.dfci.harvard.edu/</ext-link> (<xref ref-type="bibr" rid="bib20">Fu et al., 2020</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig2-figsupp3-v2.tif"/></fig></fig-group><media id="video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-64370-video2.mp4"><label>Video 2.</label><caption><title>Time-lapse video recording of Oregon Green 488-labeled gelatin degradation upon SATB2 induction in human melanoma cell line A375.</title></caption></media><p>To further validate whether the internal organ involvement in MCR:SATB2 primary tumors was due to an increased migratory potential in vivo, we used an orthotopic allotransplantation model in sub-lethally irradiated transparent <italic>casper</italic> zebrafish (<xref ref-type="bibr" rid="bib28">Heilmann et al., 2015</xref>; <xref ref-type="bibr" rid="bib46">Li et al., 2011</xref>; <xref ref-type="bibr" rid="bib91">White et al., 2008</xref>). First, we allotransplanted zebrafish melanoma-derived cell lines Zmel1 (MCR:EGFP) vs. 45–3 (MCR:SATB2) into irradiated <italic>casper</italic> recipients. This showed SATB2 to cause an invasive histological phenotype and reduction in the recipient’s overall survival compared to EGFP (45-3; n = 31, median survival = 25 days vs. Zmel1; n = 31, median onset not reached at the experimental end point) (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A–C</xref>). We then tested whether this difference was also present in primary tumors using an established in vivo migration assay (<xref ref-type="bibr" rid="bib28">Heilmann et al., 2015</xref>) where we transplanted 300,000 primary pigmented melanoma cells into <italic>casper</italic> recipients, and monitored the formation of distant metastasis (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). One week post-transplantation, 18.6% (11/59) of MCR:SATB2 recipients already developed metastases while none were observed in MCR:EGFP recipients (0/27) (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>). At the experimental end point at 3–3.5 weeks-post transplantation, 59.4 ± 2.3% (SEM; n = 76 total recipients grafted from seven individual donor tumors) of MCR:SATB2 transplants formed distant metastasis, compared to 21.8 ± 4.5% (SEM; n = 37 total recipients grafted from five individual donor tumors) of EGFP-control transplants (two-tailed <italic>t</italic>-test p&lt;0.0001) (<xref ref-type="fig" rid="fig2">Figure 2G–J</xref>, and <xref ref-type="video" rid="video3">Videos 3</xref>–<xref ref-type="video" rid="video4">4</xref>). In <italic>casper</italic> recipients that formed metastases, MCR:EGFP transplants developed an average of 1.1 ± 0.4 (SD) distant metastases per fish, versus 4 ± 4.2 (SD) in MCR:SATB2, where a maximum of 20 metastases per fish was observed (<xref ref-type="fig" rid="fig2">Figure 2G</xref>) (2-tailed <italic>t</italic>-test p&lt;0.0001). Metastases most commonly spread to hypodermal sites (<xref ref-type="fig" rid="fig2">Figure 2H–J</xref>), similar to <italic>in-transit</italic> metastases that occur in human melanoma. MCR:SATB2 recipients more frequently developed bilateral metastases (28.9% versus 5.4% in MCR:EGFP), and internal metastases (22.4% versus 5.4%) which regularly spread along the neural tube (14.5% versus 2.7%) (<xref ref-type="fig" rid="fig2">Figure 2H–I</xref>). Collectively, these in vitro and in vivo data suggest that SATB2-overexpression induces invadopodia formation, increased migration and metastasis. SATB2 is endogenously expressed in human melanoma at the RNA (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>) and protein level (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B</xref>). Human melanoma patient genomic datasets publicly available on cBio portal show SATB2 to be infrequently but recurrently amplified in ~4–8% of patients (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3C</xref>) in three independent datasets of metastatic melanoma (<xref ref-type="bibr" rid="bib33">Hugo et al., 2016</xref>; <xref ref-type="bibr" rid="bib81">Snyder et al., 2014</xref>; <xref ref-type="bibr" rid="bib86">Van Allen et al., 2015</xref>), and it’s high mRNA expression level correlate with poor survival in two independent metastatic melanoma patient datasets available on TIDE portal (GSE22153 and GSE8401, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3D</xref>).</p><media id="video3" mime-subtype="mp4" mimetype="video" xlink:href="elife-64370-video3.mp4"><label>Video 3.</label><caption><title>MCR control primary tumor transplant into transparent <italic>Casper</italic> zebrafish, 3.5 weeks post-transplant.</title></caption></media><media id="video4" mime-subtype="mp4" mimetype="video" xlink:href="elife-64370-video4.mp4"><label>Video 4.</label><caption><title>MCR:SATB2 primary tumor transplant into transparent <italic>Casper</italic> zebrafish, 3.5 weeks post-transplant.</title></caption></media></sec><sec id="s2-3"><title>SATB2 binds and transcriptionally regulates neural crest- and EMT-associated loci</title><p>To gain insight into the mechanism underlying the SATB2-overexpression phenotype in melanoma, we performed ChIP-seq and RNA-seq on primary zebrafish tumors. We conducted ChIP-seq on MCR:SATB2 primary zebrafish melanomas to identify SATB2-bound target genes. Of the panel of anti-SATB2 antibodies we tested (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>) only SC-81376 worked for ChIP-seq. While the anti-SATB2 antibody SC-81376 cross-reacted with human SATB1 it did not recognize the endogenous zebrafish gene (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), and as such should be specific for SATB2 in the MCR:SATB2 tumors. HOMER motif analysis of ChIP-seq significant peaks for de novo motif underlying SATB2 (Special AT-rich Sequence-Binding protein 2) binding showed the top motif to be AT-rich (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>) as expected (<xref ref-type="bibr" rid="bib27">Hassan et al., 2010</xref>; <xref ref-type="bibr" rid="bib60">Naik and Galande, 2019</xref>; <xref ref-type="bibr" rid="bib74">Savarese et al., 2009</xref>; <xref ref-type="bibr" rid="bib101">Zhou et al., 2012</xref>). GREAT analysis of GO-terms associated with ChIP-seq peaks, showed SATB2 binding to be enriched at loci associated with NC development and migration, and EMT (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Indeed, ~38.8% (127/327) of known NC-associated genes (<xref ref-type="bibr" rid="bib83">Tan et al., 2016</xref>), including <italic>sox10</italic>, <italic>snai2, pax7, chd7, and semaforin</italic> (<italic>sema3fa</italic>) are bound by SATB2 (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). We next performed ChIP-seq for H3K27Ac and H3K9me3 histone marks in MCR:SATB2 and MCR:EGFP control tumors to investigate the effect of SATB2 overexpression on the chromatin state of SATB2-bound targets. Globally, genome-wide GO term analysis of loci with increased H3K27Ac deposition in MCR:SATB2 vs. MCR:EGFP also showed an increased activation of neural crest development (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). Furthermore, HOMER motif analysis of known motifs shows SATB2 ChIP-seq to be enriched for TFAP2A and RXR motifs, which are both transcription factors involved in neural crest specification (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). Locally, H3K27Ac deposition in MCR:SATB2 vs. MCR:EGFP around transcriptional start sites (TSS) of SATB2-bound genes suggested an increased chromatin activation state of SATB2-bound NC targets (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>SATB2 binds and regulates EMT and neural crest-associated genes.</title><p>(<bold>A</bold>) GO-term enrichment of SATB2-bound loci (GREAT analysis) from anti-SATB2 ChIp-seq on MCR:SATB2 tumors. Genes are defined as bound if SATB2 peaks are found within 3 kb of the transcriptional start (TSS) or end site (TES), and the gene body (GB). (<bold>B</bold>) H3K27Ac and H3K9me3 TSS +/- 2 Kb profile of H3K27Ac at SATB2 bound targets comparing MCR:SATB2 in red and MCR:EGFP in green. (<bold>C</bold>) ChIP-seq and significant differentially expressed genes RNA-seq (p&lt;0.05, q &lt; 0.05, FC&gt;|1.5|) overlap was performed on primary zebrafish tumors to identify SATB2-bound genes that are misregulated. (<bold>D</bold>) qRT-PCR validation of transcriptionally altered SATB2-bound and associated targets associated to neural crest development, and the actin cytoskeleton and extracellular matrix. Symbols indicate single primary tumors, normalized to β-actin. *p&lt;0.05, ***p&lt;0.0001, ****p&lt;0.0001. SATB2-bound genes are highlighted in purple. (<bold>E</bold>) Whole mount primary tumor immunohistochemistry for E-cadherin (red), scale bar is 100 μm, Vimentin (green), scale bar is 100 μm, Fibronectin 1 (red), scale bar is 50 μm, and Collagen 1 (red), scale bar is 50 μm, Dapi (blue). (<bold>F</bold>) Injection in MCR model as described in <xref ref-type="fig" rid="fig1">Figure 1A</xref> of MCR:EGFP, and MCR:SNAI2. (Log-rank (Mantel-Cox) test p&lt;0.0001****). (<bold>G</bold>) Gross anatomy of zebrafish injected with MCR:SNAI2. Arrows show melanomas. (<bold>H</bold>) H and E representative histology of MCR:EGFP, MCR:SATB2, and MCR:SNAI2 tumors. Black bar is 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Analysis of SATB2 expression and chromatin effect in human and zebrafish melanoma.</title><p>(<bold>A</bold>) Western blot analysis in MCR:EGFP, MCR:SATB2, and MCR:SATB1 zebrafish tumors of SATB2 expression and antibody cross reactivity with human SATB1 (in MCR:SATB1) and lack of detection of endogenous zebrafish satb1. The SC-81376 antibody was used for anti-SATB2 ChIP-seq in MCR:SATB2 tumors, since the other anti-SATB2 antibodies shown in <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B</xref> did not work in immunoprecipitation. (<bold>B</bold>) HOMER motif prediction analysis of significant peaks (P&lt;E-9) from anti-SATB2 ChIP-seq enrichment over input in MCR:SATB2 tumors showing the top motif to be AT-rich as expected. (<bold>C</bold>) HOMER known motifs enrichment analysis on anti-SATB2 ChIP-seq peaks with p&lt;E-9 in MCR:SATB2 (<bold>D</bold>) Go-term enrichment analysis of genome-wide H3K27Ac peaks enriched in MCR:SATB2 over MCR:EGFP Around TSS Log2FC &gt; 1(GREAT analysis). (<bold>E</bold>) RNA-seq analysis of <italic>satb2</italic> expression in sorted <italic>crestin:EGFP<sup>+</sup></italic> developing neural crest cells (data source7). (<bold>F</bold>) Knock-down of <italic>satb2</italic> in the transgenic neural crest reporter line Tg(<italic>sox10:mCherry)</italic> using a validated morpholino for <italic>satb2</italic>. While <italic>satb2</italic> knock down did not affect melanocyte development (0/120), <italic>satb2</italic> morphants displayed severe cranio-facial abnormalities as observed by overall reduced <italic>sox10</italic> reporter expression, reduced pectoral fins, and head size (109/120) (arrows). (<bold>G</bold>) Example analysis of the chromatin state of a direct SATB2 target showing the <italic>pdgfab</italic> locus. ChIP-Seq track in zebrafish MCR:SATB2 for SATB2 (in black). ChIP-seq tracks for H3K27Ac and H3K9me3 in primary tumors MCR:SATB2 (red) and MCR:EGFP controls (green).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig3-figsupp1-v2.tif"/></fig></fig-group><p>SATB2’s binding pattern is consistent with its role as a necessary specifier of cranial migratory neural crest differentiation in exo-mesenchymal tissues in the pharyngeal arches (which will develop into the jaw and teeth), and the consequent cleft palate defects observed in patients with mutated <italic>SATB2</italic> in the human SATB2 syndrome (<xref ref-type="bibr" rid="bib99">Zarate and Fish, 2017</xref>). Consistent with these prior literature findings, <italic>satb2</italic> is highly expressed in a published dataset of migrating <italic>crestin:EGFP</italic><sup>+</sup>-NC cells sorted from zebrafish embryos at the 15 somite stage (<xref ref-type="bibr" rid="bib40">Kaufman et al., 2016</xref>), when EMT-mediated delamination initiates migration of the neural crest, including cranial-NC (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). Furthermore, knock-down of <italic>satb2</italic> during embryonic development via microinjection of a validated splicing morpholino (<xref ref-type="bibr" rid="bib4">Ahn et al., 2010</xref>) in the transgenic neural crest reporter zebrafish line Tg(<italic>sox10:mCherry</italic>) showed a reduction of <italic>sox10</italic> reporter expression and craniofacial abnormalities, but did not affect melanocyte development (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>).</p><p>To define the transcriptional effect of SATB2-overexpression we performed RNA-seq on 3 MCR:SATB2 and 3 MCR:EGFP tumors, and correlated SATB2-bound loci with their transcriptional changes in MCR tumors to identify SATB2 target genes that might underlie SATB2’s phenotype (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Given the inter-tumor transcriptional variability of primary zebrafish tumors (evident by qPCR on SATB2 itself in MCR:SATB2 tumors, <xref ref-type="fig" rid="fig3">Figure 3D</xref>), we conducted extended validation on a subset of these bound and transcriptionally altered genes, plus some additional manually curated SATB2-bound genes by qPCR on a large set of primary tumors (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Genes that are SATB2-bound (within 3 kb of the transcriptional start or end site, and the gene body) or SATB2-associated (predicted nearest gene association), which were altered by RNA-seq revealed that NC, cytoskeleton and extracellular matrix-associated gene programs are highly stimulated by SATB2-overexpression (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). <italic>chd7</italic> and <italic>snai2</italic> in particular have been described to be key regulators of the migratory NC (<xref ref-type="bibr" rid="bib6">Bajpai et al., 2010</xref>; <xref ref-type="bibr" rid="bib65">Okuno et al., 2017</xref>; <xref ref-type="bibr" rid="bib75">Schulz et al., 2014</xref>), while <italic>pdgfab</italic> has been implicated in podosome and invadopodia formation (<xref ref-type="bibr" rid="bib17">Ekpe-Adewuyi et al., 2016</xref>; <xref ref-type="bibr" rid="bib59">Murphy and Courtneidge, 2011</xref>; <xref ref-type="bibr" rid="bib58">Murphy et al., 2011</xref>; <xref ref-type="bibr" rid="bib67">Paz et al., 2014</xref>). SATB2-binding to targets such as <italic>pdgfab</italic> (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G</xref>), results in increased H3K27Ac deposition along the promoter, TSS region and gene body in MCR:SATB2 compared to MCR:EGFP, respectively.</p><p>To investigate whether in MCR:SATB2 tumors cell fate rewiring functionally induces an EMT-like phenotype-switch reminiscent of the CNC development, we performed whole mount immunofluorescence for EMT markers on primary zebrafish melanomas. Indeed, compared to MCR:EGFP, MCR:SATB2 tumors showed mislocalized E-cadherin, and an increased protein expression of Vimentin and extracellular matrix attachment proteins Fibronectin 1 (<italic>fn1a/b</italic>) and Collagen 1 (<italic>col1a1a/b</italic>) (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Given the known role of <italic>snai</italic> family of proteins in regulating EMT we tested whether SATB2’s direct downstream target <italic>snai2</italic> could recapitulate the MCR:SATB2 phenotype in vivo. Overexpression of SNAI2 resulted in a significant acceleration of tumor onset compared to the EGFP negative control (<xref ref-type="fig" rid="fig3">Figure 3F</xref>), albeit milder than SATB2 (MCR:SNAI2 median onset 18 weeks vs 12 weeks for MCR:SATB2). Similar to MCR:SATB2 (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), and unlike MCR:EGFP, MCR:SNAI2 fish showed development of multiple tumors (<xref ref-type="fig" rid="fig3">Figure 3G</xref>), with a histopathologically invasive morphology (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Overall, SATB2 binds and activates chromatin at a subset of neural crest-related loci including <italic>snai2</italic>, resulting in an EMT-like phenotype. Overexpression of the human ortholog of downstream target <italic>snai2</italic> partially recapitulates SATB2’s phenotype in the MCR model.</p></sec><sec id="s2-4"><title>SATB2-induced program is conserved across zebrafish and human melanoma and overlaps with known drug resistance transcriptional states</title><p>To ascertain whether SATB2-induced transcriptional changes were conserved across species, we induced SATB2 overexpression in primary human melanocytes and human melanoma cell lines, and performed qPCR for selected orthologs of genes validated in zebrafish. qPCR analysis of SATB2 target genes after 48 hr of culture in the presence of doxycycline on iSATB2 melanoma cell lines (SKMEL2, A375, and SKMEL28 iSATB2), and iSATB2 untransformed primary human melanocytes (HEMA-LP) showed a similar increase in SNAI transcription factors (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Cell-line-specific differences in overall <italic>SNAI1</italic> or <italic>SNAI2</italic> (both <italic>snai2</italic> orthologs) induction levels may reflect context dependence (e.g. oncogene or cell line baseline status) (<xref ref-type="bibr" rid="bib64">Nieto et al., 2016</xref>). To analyze global transcriptional changes induced by SATB2 in human melanoma, we selected SKMEL2 iSATB2, since this cell line had the lowest endogenous SATB2 level and showed the strongest invadopodia induction (<xref ref-type="fig" rid="fig2">Figure 2D–E</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). We conducted RNA-seq on SKMEL2 iSATB2 after 48 hr of treatment with doxycycline. Both Gene Set Enrichment Analysis (GSEA) Hallmark pathways analysis and Ingenuity Pathway Analysis (IPA) (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) of significant genes, showed similar effects of SATB2 overexpression between the human melanoma cell line (SKMEL2 iSATB2 p&lt;0.01; <italic>q</italic> &lt; 0.01; FC &gt; 2) and zebrafish tumors (MCR:SATB2 vs. EGFP p&lt;0.01; <italic>q</italic> &lt; 0.01; FC &gt; 1.5) with strong similarity in the top significant pathways across human and zebrafish melanoma. These overlaps included pathways related to EMT/mesenchymal activation, osteoblast changes, axonal guidance, semaphorins, cancer metastasis, WNT, and TGFB signaling (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). SATB2-overexpression (SKMEL2 iSATB2 RNA-seq) induced consistent transcriptional changes in several NC and invadopodia regulators, including activation of human orthologs of <italic>pdgfab</italic> and <italic>snai2</italic> (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). These similarities across species, overexpression systems, and in vitro vs. in vivo conditions consolidate our findings.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Conservation between transcriptional effects induced by SATB2 in zebrafish and human melanoma, and between the SATB2-program and known drug-resistant cell states.</title><p>(<bold>A</bold>) Overexpression of SATB2 with TETon (iSATB2) in normal human epidermal melanocytes (HEMA-LP) and in SKMEL2, SKMEL28, and A375 melanoma cells is sufficient to induce transcriptional activation of <italic>SOX10</italic>, <italic>SNAI1/2, PDGFB,</italic> and SEMA3F mRNA. qRT-PCR Data was normalized to beta-actin, and fold change was determined compared to un-induced controls. *p&lt;0.05, **p&lt;0.001, ***p&lt;0.0001, ****p&lt;0.0001. (<bold>B</bold>) Overlap of Ingenuity Pathway Analysis and Gene Set Enrichment Analysis Hallmark pathways of RNA-seq in MCR zebrafish tumors and iSKMEL2 human (plus vs. minus doxycycline) melanoma cell line. For IPA humanized significant zebrafish genes were used (p&lt;0.05, q &lt; 0.05, FC&gt;|1.5|=1044 zf-&gt;840 unique human orthologs), and significant SKMEL2 iSATB2 genes (p&lt;0.05, q &lt; 0.05, FC&gt;|1|). (<bold>C</bold>) Curated heatmap of altered genes in RNA-seq of human SKMEL2 cells overexpressing SATB2 (plus DOX vs. minus DOX FC &gt;1; p&lt;0.01) that have been involved in neural crest or Rambow Neural crest-like state, PDGF-PDGFR-SRC invadopodia cascade, AXL/MITF state and melanocyte differentiation. All genes shown are significantly altered except for TFAP2C. Normalized RNA-seq heatmap of expression fold change Z-score is plotted. Genes part of the neural crest GRN are highlighted in blue, invadopodia related genes are highlighted in green, and MAPK inhibitors resistance genes are highlighted in magenta. (<bold>D</bold>) Gene set enrichment analysis (GSEA) of 1000 MSigDB signatures including the states described by Tirosh et al. and Rambow et al.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>IPA analysis of significant differentially expressed genes in SKMEL2 iSATB2.</title><p>IPA analysis on (<bold>A</bold>) pathways and (<bold>B</bold>) disease functions on SKMEL2 iSATB2. Related to <xref ref-type="fig" rid="fig4">Figure 4B–C</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig4-figsupp1-v2.tif"/></fig></fig-group><p>To asses how the SATB2 program relates to previously described transcriptional states in melanoma, we conducted GSEA analysis in SKMEL2 iSATB2 for known signatures: (1) a mesenchymal signature (<xref ref-type="bibr" rid="bib89">Verfaillie et al., 2015</xref>), (2) MITF<sup>low</sup>/AXL<sup>high</sup> drug resistance state (<xref ref-type="bibr" rid="bib84">Tirosh et al., 2016</xref>), and (3) neural crest state and other transcriptional signatures in different tumor cell subpopulations (<xref ref-type="bibr" rid="bib72">Rambow et al., 2018</xref>). This analysis showed a significant overlap of the SATB2-induced transcriptional program with the less differentiated MITF<sup>low</sup>/AXL<sup>high</sup> state (NES = 1.54, p=0.000, <italic>q</italic> = 0.17), and the Rambow neural crest-like/minimal residual disease MITF<sup>low</sup>/NGFR1<sup>high</sup>/AQP1<sup>high</sup> state driven by <italic>RXRG</italic> (NES = 1.64, p=0.000, <italic>q</italic> = 0.09) (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), which have both been previously described in metastatic human melanoma to correlate with a self-renewing MAPK inhibitor drug-resistant state (<xref ref-type="bibr" rid="bib72">Rambow et al., 2018</xref>; <xref ref-type="bibr" rid="bib84">Tirosh et al., 2016</xref>). The key marker genes of these states (i.e. <italic>AQP1, RXRG, NGFR, AXL,</italic> <xref ref-type="fig" rid="fig4">Figure 4C</xref>) and additional genes involved in MAPK resistance (i.e. SRC and PDGF pathway members (<xref ref-type="bibr" rid="bib17">Ekpe-Adewuyi et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Nazarian et al., 2010</xref>; <xref ref-type="bibr" rid="bib73">Rebecca et al., 2014</xref>), <xref ref-type="fig" rid="fig4">Figure 4C</xref>) and RXR-related pathways (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–B</xref>) are significantly induced by SATB2 overexpression. Overall, SATB2 drives a transcriptional induction of invadopodia, EMT and neural crest regulators in zebrafish and human melanoma alike, consistent with the transcriptional changes and phenotypes described above and its known role in development. Furthermore, the SATB2-induced transcriptional program shows strong overlaps with known drug-resistance transcriptional states in melanoma.</p></sec><sec id="s2-5"><title>SATB2 increases tumor propagating potential and resistance to MAPK inhibition in vivo</title><p>Given the overlap between the SATB2-induced program and the known minimal residual disease and MAPK pathway inhibition-resistant states, we asked whether SATB2 functionally confers enhanced self-renewal or resistance to MAPK pathway inhibition. To address the former, we performed a limiting dilution tumor propagation assay injecting 300,000, 3000, 300, or 30 primary pigmented melanoma cells from MCR:EGFP (n = 4) and MCR:SATB2 (n = 5) donor tumors, into the dorsum of the zebrafish (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). While MCR:EGFP did not display engraftment with fewer than 3000 cells (0/28), 44% (4/9) of MCR:SATB2 engrafted with 30 cells (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). SATB2 donors have a significantly higher estimated fraction of tumor propagating cells (median estimate 1/21.6 cells for MCR:SATB2 vs. 1/10,879 cells for MCR:EGFP, Mann Whitney p=0.0159*; <xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>MCR:SATB2 tumor allografts have higher tumor propagating potential and resistance to Vemurafenib in vivo.</title><p>(<bold>A</bold>) Weekly time lapse photography of a representative MCR:SATB2 melanoma cell recipient. Black arrows indicate metastases, which can already be observed 1 week post-transplantation. Related to <xref ref-type="fig" rid="fig2">Figure 2E–I</xref>. (<bold>B</bold>) Subcutaneous primary melanoma limiting dilution transplantation model in transparent <italic>Casper</italic> zebrafish. 300,000, 3000, 300, or 30 primary pigmented primary melanoma cells were transplanted into a subcutaneous space in running along the dorsum of irradiated <italic>Casper</italic> recipients. Ten to 12 animals per condition were used, and a total of four MCR:EGFP and five MCR:SATB2 donors were transplanted over the course of two independent experiments. (<bold>C</bold>) Representative images of MCR:EGFP and MCR:SATB2 recipients transplanted with 30 cells. (<bold>D</bold>) Engraftment of surviving recipients at 3 weeks post-transplant was used to estimate the frequency of tumor propagating cell potential with Extreme Limiting Dilution Analysis (ELDA). Estimated frequency of tumor propagating cells between MCR:EGFP and MCR:SATB2 donors (Mann-Whitney, p&lt;0.0159*). (<bold>D</bold>) In vivo drug treatment of allotransplanted primary MCR:EGFP or MCR:SATB2 tumors with FDA-approved BRAF inhibitor Vemurafenib shows confirms SATB2 as a resistance driver. Recipients casper fish were treated by daily oral gavage with 100 mg/kg of drug or vehicle control from day 10 post-transplant to day 24 post-transplant. Animals were imaged at day 10 and 24 and pigmented tumor area was estimated using digital calipers to assess treatment response. (<bold>E</bold>) Representative image of individual treated animals. (<bold>F</bold>) Mean normalized area % change in the treated cohorts: MCR:EGFP DMSO (n = 11) +12.45, SEM 2.55 vs. MCR:EGFP BRAFi (n = 12)–50.67, SEM 7.26 vs. MCR:SATB2 DMSO (n = 17) +11.06, SEM 1.84 vs. MCR:SATB2 BRAFi (n = 16) +22.06, SEM 2.81. Unpaired two-tailed t-test p values of pairwise comparisons are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64370-fig5-v2.tif"/></fig><p>To test whether the SATB2-induced program confers resistance to MAPK pathway inhibition, we utilized an established in vivo drug treatment assay (<xref ref-type="bibr" rid="bib15">Dang et al., 2016</xref>) where primary zebrafish melanoma are allotransplanted in irradiated <italic>casper</italic> recipients and administered a BRAFi (Vemurafenib 100 mg/kg) daily via oral gavage starting at day 10 post transplant (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Analysis of tumor growth by measuring tumor area with digital calipers after 2 weeks (day 24 post-transplant) of treatment with Vemurafenib or a DMSO vehicle control showed a complete lack of response in MCR:SATB2 compared to Vemurafenib sensitive MCR:EGFP tumors (<xref ref-type="fig" rid="fig5">Figure 5E–F</xref>) (MCR:EGFP BRAFi vs. MCR:SATB2 BRAFi 2-tailed <italic>t</italic>-test p&lt;0.0001****). Our data functionally validate SATB2 as a driver of enhanced tumor propagation and drug resistance in vivo.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we investigated the effect of epigenetic and transcriptional regulators on melanoma development, by in vivo perturbation in endogenous tumors. We screened 80 human chromatin factors using a pooled screening approach in a transgenic zebrafish melanoma model driven by the most common melanoma oncogene, <italic>BRAF<sup>V600E</sup></italic>, and loss of the tumor suppressor <italic>tp53</italic> (<xref ref-type="bibr" rid="bib11">Cancer Genome Atlas Network, 2015</xref>). This experimental approach could be used to try to identify pools/genes that can accelerate (e.g. SATB2, <xref ref-type="fig" rid="fig1">Figure 1C</xref>) or delay (e.g. CBX3, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>) tumor onset. Both for biological and for technical reasons we chose to focus on accelerators including: (1) A longer screen follow up time is required to identify pools/genes slowing tumor onset and (2) the likelihood of false positives in delayed tumor onset from perturbation resulting in development toxicity is higher. Through single factor validation of pool F, which had the strongest acceleration phenotype, we identified transcriptional regulator SATB2 as a potent accelerator of melanoma onset in zebrafish (<xref ref-type="fig" rid="fig1">Figure 1B–C</xref>, <xref ref-type="video" rid="video1">Video 1</xref>). Of the other six significant genes identified in the screen (TRIM28, CDYL2, DMAP1, CBX5, PYGO2, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–D</xref>), TRIM28 is known to increase melanoma tumor propagation potential (<xref ref-type="bibr" rid="bib14">Czerwinska et al., 2020</xref>).</p><p>MCR:SATB2 transgenic animals, in addition to developing tumors faster, had a high prevalence of tumor burden in internal organs, which is uncommon in MCR:EGFP controls, even in animals with very large tumors (<xref ref-type="fig" rid="fig1">Figure 1D–G</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D–E</xref>). This has not been previously observed with several other accelerators or drug resistance drivers that we and others have identified using the MiniCoopR model (<xref ref-type="bibr" rid="bib2">Ablain et al., 2018</xref>; <xref ref-type="bibr" rid="bib12">Ceol et al., 2011</xref>; <xref ref-type="bibr" rid="bib15">Dang et al., 2016</xref>; <xref ref-type="bibr" rid="bib19">Fazio et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">Iwanaga et al., 2020</xref>; <xref ref-type="bibr" rid="bib40">Kaufman et al., 2016</xref>; <xref ref-type="bibr" rid="bib88">Venkatesan et al., 2018</xref>).</p><p>This phenotype could be explained by a proliferation effect resulting in multiple parallel tumor initiation events in both dermal and internal melanocytes (<xref ref-type="bibr" rid="bib39">Kapp et al., 2018</xref>), or by an early invasive migration and metastasis phenotype. We did not observe proliferation differences between MCR:SATB2 and MCR:EGFP (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A</xref>), nor in a panel of three human melanoma cell lines upon inducible overexpression of SATB2 (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4B–C</xref>). On the other hand SATB2 overexpression in cultured zebrafish tumors (<xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–D</xref>) and human melanoma cell lines (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>, and <xref ref-type="video" rid="video2">Video 2</xref>) resulted in increased invasion in vitro, and MCR:SATB2 zebrafish primary tumor allografts in irradiated optically clear <italic>casper</italic> recipients had a much higher distant and internal metastasis rate compared to MCR:EGFP controls (<xref ref-type="fig" rid="fig2">Figure 2F–J</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>, and <xref ref-type="video" rid="video3">Videos 3</xref>–<xref ref-type="video" rid="video4">4</xref>), suggesting the latter hypothesis to be more likely at the basis of our observations in tumor-bearing MCR:SATB2 transgenic fish.</p><p>Our chromatin and transcriptional analysis via ChIP-seq, and RNA-seq followed by qPCR validation on MCR:SATB2 vs. MCR:EGFP control tumors showed SATB2 to directly bind and transcriptionally induce several genes related to neural crest development (<italic>snai2</italic> and <italic>chd7</italic>) (<xref ref-type="bibr" rid="bib6">Bajpai et al., 2010</xref>; <xref ref-type="bibr" rid="bib7">Betancur et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">Mayor and Theveneau, 2013</xref>; <xref ref-type="bibr" rid="bib75">Schulz et al., 2014</xref>), EMT (<italic>vim</italic> and <italic>fn1</italic>) (<xref ref-type="bibr" rid="bib7">Betancur et al., 2010</xref>), and invadopodia formation (<italic>pdgfab</italic> and <italic>rhobtb2</italic>) (<xref ref-type="bibr" rid="bib49">Maheswaran and Haber, 2015</xref>; <xref ref-type="bibr" rid="bib53">Mayor and Theveneau, 2013</xref>; <xref ref-type="bibr" rid="bib59">Murphy and Courtneidge, 2011</xref>; <xref ref-type="bibr" rid="bib64">Nieto et al., 2016</xref>; <xref ref-type="bibr" rid="bib67">Paz et al., 2014</xref>). Functionally, an EMT-like phenotype and ECM remodeling in MCR:SATB2 vs. MCR:EGFP tumors was also apparent at the protein level (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), and SATB2 overexpression induced the formation of functional invadopodia with ECM degrading capacity in zebrafish tumors, primary cell lines, and human melanoma cell lines alike (<xref ref-type="fig" rid="fig2">Figure 2A–E</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B–E</xref>, and <xref ref-type="video" rid="video2">Video 2</xref>). This neural crest mesenchyme-like program outlined above is consistent with SATB2’s known roles in the development of exo-mesenchymal derivatives of the CNC (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E–F</xref>; <xref ref-type="bibr" rid="bib4">Ahn et al., 2010</xref>; <xref ref-type="bibr" rid="bib27">Hassan et al., 2010</xref>; <xref ref-type="bibr" rid="bib41">Kikuiri et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Nanni et al., 2019</xref>; <xref ref-type="bibr" rid="bib71">Rainger et al., 2014</xref>; <xref ref-type="bibr" rid="bib77">Sheehan-Rooney et al., 2010</xref>; <xref ref-type="bibr" rid="bib78">Sheehan-Rooney et al., 2013</xref>; <xref ref-type="bibr" rid="bib98">Zarate et al., 2019</xref>; <xref ref-type="bibr" rid="bib99">Zarate and Fish, 2017</xref>; <xref ref-type="bibr" rid="bib102">Zhou et al., 2016</xref>), neuronal development and axon guidance (<xref ref-type="bibr" rid="bib26">Gyorgy et al., 2008</xref>; <xref ref-type="bibr" rid="bib55">McKenna et al., 2015</xref>; <xref ref-type="bibr" rid="bib79">Shinmyo and Kawasaki, 2017</xref>), and regulation of EMT/invadopodia in other solid tumors (<xref ref-type="bibr" rid="bib22">Gan et al., 2017</xref>; <xref ref-type="bibr" rid="bib50">Mansour et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Naik and Galande, 2019</xref>; <xref ref-type="bibr" rid="bib93">Wu et al., 2016</xref>; <xref ref-type="bibr" rid="bib94">Xu et al., 2017</xref>; <xref ref-type="bibr" rid="bib96">Yu et al., 2017a</xref>). EMT and invadopodia formation are, in fact, inherent to migration of the neural crest itself, since neural crest cells are specified in proximity of the neural plate, undergo EMT and rely upon podosomes, termed invadopodia in cancer cells, to remodel the ECM and migrate through the body (<xref ref-type="bibr" rid="bib5">Bailey et al., 2012</xref>; <xref ref-type="bibr" rid="bib7">Betancur et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">Mayor and Theveneau, 2013</xref>; <xref ref-type="bibr" rid="bib59">Murphy and Courtneidge, 2011</xref>; <xref ref-type="bibr" rid="bib58">Murphy et al., 2011</xref>). Reactivation of neural crest regulator <italic>snai2</italic> has been shown to increase the transformation and migration potential of melanoma (<xref ref-type="bibr" rid="bib25">Gupta et al., 2005</xref>; <xref ref-type="bibr" rid="bib80">Shirley et al., 2012</xref>). Overexpression of human SNAI2 in the MiniCoopR model similarly resulted in faster tumor development compared to EGFP controls (Log-rank (Mantel-Cox) test p&lt;0.0001), although not to the same extent as SATB2 (MCR:SNAI2 median onset 18 weeks, MCR:SATB2 median onset 12 weeks, MCR:EGFP median onset ~22 weeks in both experiments; (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig3">Figure 3F–G</xref>)) and similar invasive histological features compared to MCR:SATB2 tumors (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Taken together, these data suggest that downstream SATB2 target <italic>snai2</italic> is partially responsible for the SATB2 phenotype, but that other genes in the program contribute to the full phenotype spectrum. PDGF ligands and their receptor PDGFRB are of particular interest as additional downstream effectors, and further studies should be performed given their known role in EMT (<xref ref-type="bibr" rid="bib17">Ekpe-Adewuyi et al., 2016</xref>), invadopodia formation (<xref ref-type="bibr" rid="bib13">Charbonneau et al., 2016</xref>; <xref ref-type="bibr" rid="bib59">Murphy and Courtneidge, 2011</xref>; <xref ref-type="bibr" rid="bib70">Quintavalle et al., 2010</xref>), and acquired resistance to BRAF inhibition (<xref ref-type="bibr" rid="bib63">Nazarian et al., 2010</xref>; <xref ref-type="bibr" rid="bib73">Rebecca et al., 2014</xref>).</p><p>To further assess the conservation and relevance of our findings to human melanoma, we conducted qPCR analysis on a panel of iSATB2 human melanoma cell lines and primary cultured melanocytes (HEMa-LP). qPCR of the human orthologs of <italic>snai2</italic>, <italic>pdgfab,</italic> and <italic>sema3f</italic> overall showed a similar induction as zebrafish tumors, with some variation across cell lines (<xref ref-type="fig" rid="fig3">Figures 3D</xref> and <xref ref-type="fig" rid="fig4">4A</xref>). Even though our data seem to suggest an overall program and phenotype conservation, it is likely that SATB2 transcriptional effect is to a degree context dependent and might be affected by the baseline expression levels of specific genes across cell lines (e.g. MITF baseline status). For an unbiased global transcriptional comparison, we conducted RNA-seq on human melanoma NRAS-driven cell line SKMEL2 iSATB2, since it had the strongest invadopodia phenotype, and identified transcriptional differences induced by SATB2 overexpression (with/without Dox induction for 48 hr). Significant differentially regulated genes from SKMEL2 iSATB2 were compared with zebrafish primary tumor RNA-seq (MCR:SATB2 vs. MCR:EGFP) using both Gene Set Enrichment Analysis (GSEA) and Ingenuity Pathway Analysis (IPA). Despite (1) the ortholog prediction constraints between human and zebrafish datasets that may have resulted in some expected loss of information, (2) the variation due to species genetic and functional conservation differences, and (3) the in vivo vs. in vitro conditions, we see strong conservation across the two models in the top altered pathways (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Overall, our study shows a robust transcriptional and phenotypic conservation of SATB2 overexpression effects in melanoma across human and zebrafish (<xref ref-type="fig" rid="fig2">Figure 2A–E</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B–E</xref>, <xref ref-type="fig" rid="fig3">Figure 3D</xref>, <xref ref-type="fig" rid="fig4">Figure 4B–C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–B</xref>, and <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A,C</xref>). The SATB2-driven program we describe here (<xref ref-type="fig" rid="fig4">Figure 4C–D</xref>) significantly overlaps with the recently reported MITF<sup>low</sup>/AXL <sup>high</sup> state (<xref ref-type="bibr" rid="bib84">Tirosh et al., 2016</xref>), and the neural crest-like MITF<sup>low</sup>/NGFR1<sup>high</sup>/AQP1<sup>high</sup> state (<xref ref-type="bibr" rid="bib72">Rambow et al., 2018</xref>), which are known to be less proliferative and resistant to targeted inhibitors of the MAPK pathway. It should be further noted that a similar positive correlation between the MITF<sup>low</sup>/AXL <sup>high</sup> state, PDGFRB high expression, and acquired resistance to MAPK pathway targeted inhibitors in both BRAF (e.g. SKMEL28) and NRAS (e.g. SKMEL2) mutated melanoma cell line has been previously observed (<xref ref-type="bibr" rid="bib57">Müller et al., 2014</xref>). Indeed, SATB2 overexpression in SKMEL2 (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>) induced upregulation of AXL, AQP1, RXRG, NGFR, PDGFRB, and SRC, which have all individually been reported to drive resistance to MAPK pathway inhibitors (<xref ref-type="bibr" rid="bib9">Boshuizen et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">Nazarian et al., 2010</xref>; <xref ref-type="bibr" rid="bib18">Fallahi-Sichani et al., 2017</xref>). Interestingly, <italic>SATB2</italic> has been reported as a primary hit in an unbiased overexpression screen for MAPK pathway inhibitor resistance drivers. Specifically, it was showed to induce resistance across four human melanoma cell lines to BRAF inhibitor PLX4720, which is the progenitor compound of FDA-approved BRAF inhibitor Vemurafenib (PLX4032) (<xref ref-type="bibr" rid="bib38">Johannessen et al., 2013</xref>). We sought out to functionally validate SATB2 as a resistance driver by conducting in vivo limiting dilution transplants and drug treatments with Vemurafenib using established assays in zebrafish allografts (<xref ref-type="bibr" rid="bib15">Dang et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Heilmann et al., 2015</xref>) and showed MCR:SATB2 tumors to have increased tumor propagating potential (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>), and primary resistance to Vemurafenib treatment in vivo (<xref ref-type="fig" rid="fig5">Figure 5D–F</xref>). While genetic conservation and/or pharmacokinetic differences can limit the study of drug resistance in zebrafish, the cross-species phenotype conservation between our in vivo zebrafish data, together with the in vitro evidence in human melanoma cell lines from <xref ref-type="bibr" rid="bib38">Johannessen et al., 2013</xref> validate <italic>SATB2</italic> as driver of resistance to BRAF inhibition.</p><p>Analysis of publicly available genomic datasets showed <italic>SATB2</italic> to not be recurrently altered in the TCGA dataset (<xref ref-type="bibr" rid="bib35">ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020</xref>), but its amplifications is observed in ~4–8% of patients in three independent datasets of metastatic melanoma (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3C</xref>; <xref ref-type="bibr" rid="bib32">Hugo et al., 2015</xref>; <xref ref-type="bibr" rid="bib81">Snyder et al., 2014</xref>; <xref ref-type="bibr" rid="bib85">Van Allen et al., 2014</xref>), with a similar fraction of SATB2 high-expressing patients having a higher risk of metastasis-related poor outcome in two additional datasets (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3D</xref>).</p><p>In summary, our work identifies SATB2 as a driver of invasion and resistance to Vemurafenib treatment in melanoma. Yet, further studies focused on the analysis of patient samples will be needed to assess the prevalence, and genetic/transcriptional context of SATB2 expression changes in targeted therapy and immunotherapy clinical settings. Furthermore, we show in an autochthonous transgenic tumor model that SATB2 transcriptional rewiring of melanoma towards a state similar to the less proliferative neural crest-like state described by <xref ref-type="bibr" rid="bib72">Rambow et al., 2018</xref> can drive accelerated tumor development and invasion. Our work reinforces the idea that melanoma phenotype switching and transcriptional plasticity might dynamically select a dominant state depending on environmental constraints on proliferation during different stages of the tumor’s natural history (<xref ref-type="bibr" rid="bib3">Ahmed and Haass, 2018</xref>; <xref ref-type="bibr" rid="bib10">Boumahdi and de Sauvage, 2020</xref>; <xref ref-type="bibr" rid="bib47">Li et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Marine et al., 2020</xref>).</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Zebrafish melanoma model and MiniCoopR system</title><p>Experiments were performed as outlined by <xref ref-type="bibr" rid="bib12">Ceol et al., 2011</xref>. MiniCoopR (MCR) expression constructs were created by MultiSite Gateway recombination (Invitrogen) using full-length human open-reading frames. Briefly, pools of five similarly sized MiniCoopR constructs (5 pg each), or single factors (25 pg) including MCR alone, MCR:EGFP (<xref ref-type="bibr" rid="bib12">Ceol et al., 2011</xref>), MCR:SATB2 (IOH46688, Invitrogen), MCR:SNAI2 [pCMV-SPORT6-SNAI2 HsCD00327569],and MCR:SETDB1 (<xref ref-type="bibr" rid="bib12">Ceol et al., 2011</xref>), were microinjected together with 25 pg of Tol2 transposase mRNA into one-cell Tg<italic>(BRAF<sup>V600E</sup>);p53<sup>-/-</sup>; mitf<sup>-/-</sup></italic> zebrafish embryos. Embryos were scored for melanocyte rescue at 48–72 hr post-fertilization, and equal numbers were raised to adulthood (15–20 zebrafish per tank), and scored weekly (from 8 to 12 weeks post-fertilization) or bi-weekly (&gt;12 weeks post-fertilization) for the emergence of melanoma. Macroscopically visible pigmented raised lesions were scored as melanoma as previously described (<xref ref-type="bibr" rid="bib12">Ceol et al., 2011</xref>). Prior work establishing the melanoma transgenic model showed raised lesions to be histologically and functionally malignant tumors, while benign nevi to be hyper pigmented but to remain flat and not be able to propagate tumors (<xref ref-type="bibr" rid="bib12">Ceol et al., 2011</xref>; <xref ref-type="bibr" rid="bib40">Kaufman et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">McConnell et al., 2019</xref>; <xref ref-type="bibr" rid="bib66">Patton et al., 2005</xref>). The minimum cohort size per injection was 40 animals as previously defined (<xref ref-type="bibr" rid="bib12">Ceol et al., 2011</xref>). We pre-established criteria to exclude/censor animals if they died without having been examined for tumor formation. No randomization or blinding was used. Kaplan-Meier survival curves were generated in GraphPad Prism, and statistical difference was determined by a log-rank (Mantel-Cox) test. For subsequent expression, binding and histopathological analyses, large tumors were isolated from MCR:SATB2 (9–18 weeks post-fertilization), MCR/MCR:EGFP (14–28 weeks post-fertilization, due to later tumor onset and slower progression compared to MCR:SATB2) MCR:SNAI2(14–20 weeks post-fertilization). Zebrafish were maintained under IACUC-approved conditions (Boston Children's Hospital Institutional Animal Care and Use Committee protocol # 20-10-4253R).</p></sec><sec id="s4-2"><title>CRISPR/Cas9 inactivation of <italic>satb2</italic></title><p>To specifically inactivate <italic>satb2</italic> in melanocytes, we engineered the MiniCoopR vector to express Cas9 under the control of the melanocyte-specific <italic>mitfa</italic> promoter, and a gRNA efficiently mutating <italic>satb2</italic> off a <italic>U6</italic> promoter (<xref ref-type="bibr" rid="bib1">Ablain et al., 2015</xref>). <italic>Cas9</italic> mRNA was produced by in vitro transcription from a pCS2 <italic>Cas9</italic> vector (<xref ref-type="bibr" rid="bib37">Jao et al., 2013</xref>) using mMESSAGE mMACHINE SP6 kit (Invitrogen). The <italic>satb2</italic> gRNA 5’-<named-content content-type="sequence">GGATGGGCAGGGGGTTCCAG</named-content>-3’ was generated following established methods (<xref ref-type="bibr" rid="bib21">Gagnon et al., 2014</xref>). To validate targeting, 600 pg of <italic>Cas9</italic> mRNA and 25 pg of gRNA were injected into embryos of the AB strain, and the T7E1 assay was performed as reported (<xref ref-type="bibr" rid="bib42">Kim et al., 2009</xref>), using the following primers: 5’-<named-content content-type="sequence">CCTACCTCAATCCACTCTTT</named-content>-3’ and 5’-<named-content content-type="sequence">GCTGCACCAAGAAACTACAA</named-content>-3’. Verified gRNAs against <italic>satb2,</italic> and a <italic>p53</italic> control (<xref ref-type="bibr" rid="bib1">Ablain et al., 2015</xref>) were injected into one-cell stage Tg(<italic>mitfa:BRAF<sup>V600E</sup></italic>); <italic>p53<sup>-/-</sup>; mitfa<sup>-/-</sup></italic> embryos, and tumor formation was monitored.</p></sec><sec id="s4-3"><title>Morpholino knockdown of <italic>satb2</italic></title><p>To address whether SATB2 is necessary for neural crest and melanocyte development, 4 pg of a splicing morpholino against <italic>satb2</italic> (<named-content content-type="sequence">GCAGTGTTGAACTCACCATGAGCCT</named-content>, <xref ref-type="bibr" rid="bib4">Ahn et al., 2010</xref>) was injected into one-cell stage TG(<italic>sox10:mCherry</italic>) embryos. At 3 dpf, injected and uninjected control embryos were scored for melanocyte and cranio-facial abnormalities using light and fluorescence microscopy. The experiment was repeated three times, with an average clutch size of 40 embryos per experiment.</p></sec><sec id="s4-4"><title>Zebrafish primary tumor and cell line transplants</title><p>Pigmented primary melanomas were excised from euthanized MCR/MCR:EGFP and MCR:SATB2 zebrafish, and dissociated in 50% Ham’s-12/DMEM medium containing 0.075 mg/mL liberase (Promega) for 30 min at RT, with periodical manual disaggregation using a razor blade. The dissociation medium was inactivated by the addition of 3 × 5 ml 50% Ham’s-12/DMEM with 15% heat-inactivated Fetal Bovine Serum. To obtain a single-cell suspension, cells were passaged through a 40 µm filter into a 50 mL falcon tube, and pelleted by centrifugation at 500 x g for 5 min. Cell numbers were determined, and a cell suspension of 100,000 cells/µl in PBS was made, and kept on ice. Casper recipients received a split-dose irradiation of 15 Gy over 2 consecutive days prior to transplantation (<xref ref-type="bibr" rid="bib28">Heilmann et al., 2015</xref>). During transplantation, irradiated Casper recipients were anesthetized in 0.4% MS222, mounted in a moist sponge. Using a Hamilton syringe, 300,000 pigmented primary tumor cells, or 250,000 MCR:EGFP (zmel1) or MCR:SATB2 (45–3) cells were injected into a confined interstitial subcutaneous space that runs along the dorsum of the zebrafish. Five to seven primary tumors were used per cohort, with each individual tumor being transplanted into 6–12 <italic>casper</italic> recipients. Metastatic progression, as defined by the formation of distant metastasis that have spread passed the anatomical midline, was monitored weekly or at the experimental end point at 3–3.5 weeks post-transplant, and photographically recorded using a Nikon D3100 DSLR camera. Limiting dilution experiments were performed in a similar fashion by using multiple dilutions from each individual donor and transplanting cohorts of 10 recipients per each experiment arm. Overall 4 MCR : EGFP donors and 5 MCR : SATB2 donors were transplanted in the course of three independent experiments. Recipients were monitored weekly for engraftment or at the experimental end point at 3 weeks post-transplant, and photographically recorded using a Nikon D3100 DSLR camera. The percentage of engraftment and n was used as input to estimate the fraction of tumor propagating cells using Extreme limiting dilution analysis ELDA (<xref ref-type="bibr" rid="bib31">Hu and Smyth, 2009</xref>) Statistical difference across groups was calculated with a Mann-Whitney test using GraphPad Prism. No blinding was performed, and the group size was not predetermined statistically. Statistical significance for all above experiments was determined by an unpaired two-tailed <italic>t</italic>-test unless otherwise specified, using GraphPad Prism. Drug treatment with Vemurafenib (100 mg/kg dissolved in DMSO) or with equal amount of DMSO dissolved in water was performed via daily oral gavage for 14 days starting on day 10 post-transplant on irradiated <italic>casper</italic> recipients allografted in the peritoneum with 500,000 pigmented primary tumor cells. Recipients were monitored at day 10 post-transplant before starting treatment, and at the experimental end point at day 24 post-transplant (14 of treatment), and photographically recorded using a Nikon D3100 DSLR camera. Tumor response was assessed as previously described Tumor area was measured at day 10 and day 24 using a traceable digital caliper (Fisher, 14-648-17). The pigmented tumor area was calculated by the longest measured length and width of the tumor. The drug response was quantified via the change from baseline tumor area using the RECIST (Response Efficacy Criteria in Solid Tumors). The response rate for experimental cohorts was depicted via waterfall plots, and <italic>t</italic>-test statistics were applied for significance as previously described (<xref ref-type="bibr" rid="bib15">Dang et al., 2016</xref>).</p></sec><sec id="s4-5"><title>Whole-mount tumor immunohistochemistry</title><p>Zebrafish were euthanized on ice, melanomas were surgically removed, and fixed in either 4% paraformaldehyde (PFA) or DENTS (80% methanol, 20% DMSO) overnight at 4°C. Tumors were washed at least 3 times with PBS, and mounted in 4% agarose in PBS for Vibratome sectioning. One hundred to 150 μM sections were cut using the Microm HM650V Vibratome. Sections were next processed for immunohistochemistry. PFA fixed samples were permeabilized by digestion with 15 µg/ml Proteinase K in PBS-0.1% Tween for 30 min at 37°C, or 0.4% Triton in PBS for 10 min at room temperature. After washing three times with PBS-0.1% Tween for 10 min, samples were blocked (10% lamb serum, 1% DMSO in PBS-0.1% Tween) for at least 1 hr, and incubated with primary antibodies overnight at 4°C. Antibodies used were: anti-E Cadherin (1:100, DENTs fixation; ab11512, Abcam), Anti-Vimentin (1:200; sc-6260, Santa-Cruz), anti-Collagen I (1:250; ab23730, Abcam), anti-Fibronectin 1 (1:250; F3648, Sigma Aldrich), and anti-Cortactin (p80/85), clone 4F11 (1:100; 05–180, EMD Millipore). After extensive washes with PBS-0.1% Tween, and blocking for 1 additional hour, samples were incubated in appropriate secondary Alexa-Fluor antibodies (1:500 Invitrogen) overnight at 4°C. Nuclei were counterstained with 1:1000 DAPI, and sections were mounted on a microscope slides in Slow Fade Gold (Invitrogen). Confocal images were collected on a Nikon C2si Laser Scanning Confocal using 40x water or 63x oil immersion objectives.</p></sec><sec id="s4-6"><title>Tumor histology and proliferation index</title><p>Zebrafish were fixed in 4% paraformaldehyde, decalcified, paraffin-embedded, sectioned (7 μm) and Hematoxylin and Eosin (H and E) stained by the DFCI/HCC Research and BWH pathology cores, using standard procedures. Transmitted light images were collected on a Nikon C2si Laser Scanning Confocal using a Hamamatsu camera. To determine proliferation rates, slides were incubated with Anti-Histone H3 (phospho S10; 1:250; ab5176, Abcam), and colorimetrically stained with DAB following standard procedures. The average number of PH3-positive cells per tumor was determined by counting five high-power field images (×40–×60) per tumor. An unpaired tailed Student’s T-test was used to determine significance.</p></sec><sec id="s4-7"><title>Western blot</title><p>Adherent cells were scraped, and zebrafish tumors were mechanically homogenized in RIPA lysis buffer containing 1:100 protease inhibitors (P8340, Sigma-Aldrich) and 20 µM N-ethylmaleimide (Sigma-Aldrich). Lysates were incubated for 20 min on ice, and spun down for 10 min at 14,000 RPM at 4°C. Samples were denatured by adding Laemmli sample buffer (BioRad) with 5% β-mercaptoethanol (Sigma-Aldrich), and boiled at 95°C for 5 min prior to loading. Protein concentrations were determined using the DC protein assay (BioRad). Proteins (20 µg) were separated on a 4–20% mini-PROTEAN TGX (BioRad) precast gel, and transferred onto a nitrocellulose membrane using the iBlotting system (Invitrogen). Primary antibodies used were: Anti-SATB2 (zebrafish tumors, 1 ug/ml; Ab51502, Abcam), Anti-SATB2 (human cells, 1:200; HPA029543, Sigma Aldrich) and Anti-Beta Actin (1 µg/ml; A2228, Sigma-Aldrich) as a loading control. Additional antibodies used against SATB1 and SATB2 are listed in <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>. Protein bands were detected by rabbit anti-mouse HRP (1:20,000, Pierce) or swine anti-rabbit HRP (1:20,000, Pierce).</p></sec><sec id="s4-8"><title>RNA extraction, quantitative RT-PCR analysis, and RNA-seq sample preparation</title><p>Zebrafish tumors were isolated and mechanically homogenized in 350 μl RTL buffer (Qiagen) containing β-mercaptoethanol, on ice for 20 s. Adherent cells (zebrafish and human cell culture) were washed twice with ice cold PBS on ice, and cells were scraped in RTL buffer containing β-mercaptoethanol (Sigma-Aldrich). Tumor and cell lysates were next transferred onto a QiaShredder column (Qiagen). RNA isolation was performed using the RNA micro plus kit (Qiagen), according to the manufacturers instruction. RNA quality was determined using a Nanodrop. For RNA-seq on primary zebrafish melanomas, additional quality control of the total RNA was performed on and Fragment Analyzer. Total RNA was depleted of ribosomal RNA with the RiboZero gold kit (Epicentre), and enriched mRNA was applied to library preparation according to manufacturer's protocol (NEBNext Ultra). After repeated quality control for an average DNA input size of 300 base pairs (bp), samples were sequenced on a HiSeq Illumina sequencer with 2 × 100 bp paired-end reads. For qPCR, cDNA was synthesized with the SuperScript III Kit (Life Technologies) using a 1:1 mixture of random Hexamers and OligoDT. Quantitative PCR was performed on a BioRad iQ5 real-time PCR machine using the Ssofast EvaGreen Supermix (BioRad). The ∆Ct or ∆∆Ct methods were used for relative quantification. The average of two independent experiments is shown for SKMEL2 and a single experiment is shown for primary human melanocytes. qPCR primers were designed using GETprime (<xref ref-type="bibr" rid="bib24">Gubelmann et al., 2011</xref>) or qPrimerDepot (<ext-link ext-link-type="uri" xlink:href="https://primerdepot.nci.nih.gov">https://primerdepot.nci.nih.gov</ext-link>). For primer sequences see <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>.</p></sec><sec id="s4-9"><title>Zebrafish primary melanoma cell culture</title><p>Zebrafish primary melanoma cell lines were generated as described (<xref ref-type="bibr" rid="bib28">Heilmann et al., 2015</xref>). MCR alone (CK5), MCR:EGFP (zmel1), and MCR:SATB2 (45–3 and 63–4) cell lines were cultured in DMEM medium (Life Technologies) supplemented with 10% heat-inactivated FBS (Atlanta Biologicals), 1X GlutaMAX (Life Technologies) and 1% Penicillin-Streptomycin (Life Technologies), at 28°C, 5% CO<sub>2</sub>. Zebrafish melanoma lines were authenticated by qPCR and western for human SATB2 or EGFP transgene expression, and periodically checked for mycoplasma using the Universal Mycoplasma Detection Kit (ATCC).</p></sec><sec id="s4-10"><title>Human melanoma and primary melanocytes cell culture</title><p>Human melanoma cell lines A375, SKMEL2, and SKMEL28 were obtained from the ATCC. Their identity was verified by ATCC, and they were further were regularly authenticated based on their distinct morphology. These human melanoma cell lines are not reported in the database of commonly misidentified cell lines maintained by ICLAC. They were grown in DMEM medium (Life Technologies) supplemented with 10% heat-inactivated FBS (Atlanta Biologicals), 1X GlutaMAX (Life Technologies) and 1% Penicillin-Streptomycin (Life Technologies), and grown at 37°C, 5% CO<sub>2</sub>, and periodically checked for mycoplasma using the Universal Mycoplasma Detection Kit (ATCC). Primary Human Epidermal Melanocytes from an adult lightly pigmented donor, (HEMa-LP) were obtained from ThermoFisher Scientific and cultured according to manufacturer instructions in Medium 254 supplemented with Human Melanocyte Growth Supplement-2.</p></sec><sec id="s4-11"><title>Transduction of human melanoma cell lines and primary melanocytes</title><p>The full-length human SATB2 CDS (IOH46688, Invitrogen) was cloned into pINDUCER20 (<xref ref-type="bibr" rid="bib56">Meerbrey et al., 2011</xref>) and pLenti CMV Blast DEST (706-1) (Addgene plasmid #17451 a gift from Eric Campeau and Paul Kaufman) via Gateway recombination using LR clonase II (Invitrogen) according to the manufacturers instructions. Lentiviral particles were produced by co-transfection of 293 T cells with sequence verified pINDUCER20-SATB2, pLentiCMV_SATB2_Blast, or pTK93_Lifeact (Addgene plasmid #46357 was a gift from Iain Cheeseman), and packaging plasmids pMD2.G (Addgene plasmid #12259) and psPAX2 (Addgene plasmid #12260, both gifts from Didier Trono), using FuGENE HD (Promega). Viral particles were harvested 48 and 72 hr post-transfection, concentrated by overnight PEG precipitation (<xref ref-type="bibr" rid="bib43">Kutner et al., 2009</xref>), resuspended in PBS, and stored at −80°C. Human melanoma cell lines and Hema-LP were overlaid with viral particles diluted in DMEM/1x Glutamax with 10% TET System Approved FBS (Clontech) supplemented with 5 μg/ml polybrene (Sigma-Aldrich), for 24 hr at 37°C. 48 hr post-transduction, infected cells were selected with 500 μg/ml G418 (Gibco) for 7 days (pINDUCER20-SATB2), or with 2 μg/ml puromycin (Gibco) for 3 days (pTK93_Lifeact), or with 10 μg/ml blasticidin (Gibco) for 3 days (pLentiCMV_SATB2_Blast)replacing selection medium every 48 hr.</p></sec><sec id="s4-12"><title>Matrix degradation assay</title><p>Oregon green 488-conjungated gelatin covered 12 mm coverslips, or glass bottom 6-well plates were coated as described (<xref ref-type="bibr" rid="bib52">Martin et al., 2012</xref>). Human melanoma cell lines were induced with doxycycline for 48 hr prior to plating. Human and zebrafish cells were plated at a density of 30,000 cells/well in a 12-well plate, and grown on the fluorescent gelatin for 23–25 hr at 37°C (human cells) or 28°C (zebrafish cells). Cells were fixed in 4% PFA for 10 min at room temperature, washed three times with PBS, permeabilized with 0.4% Triton-PBS for 4 min, followed by 30 min blocking (10% lab serum, 1% DMSO, 0.1% Tween in PBS). Coverslips were next stained with Alexa 650- or 568-conjungated Phalloidin (1:50) in blocking buffer, overnight at 4°C. Coverslips were washed extensively and nuclei were stained with DAPI, 10 min in PBS/0.1%Tween at RT. Coverslips were inversely mounted in Slow Fade Gold (Invitrogen) on a slide, and imaged on a Nikon C2si Laser Scanning Confocal, using ElementsX software. Experiments were seeded in triplicate, in at least three independent experiments. Four to six high-power (40-60x) areas per coverslip were imaged to determine the fraction of cells with degraded gelatin. An unpaired two-tailed <italic>t</italic>-test was used to compare significance between groups.</p></sec><sec id="s4-13"><title>Time-lapse video of fluorescent gelatin degradation after SATB2 induction</title><p>Induced human melanoma cell lines were seeded onto an Oregon green 488-conjungated gelatin coated glass bottom 6-well plate, and allowed to adhere for 3 hr at, prior to imagining. Time-lapse movies were recorded on a Nikon Eclipse Ti Spinning Disk Confocal with a ×10 objective (70 µm, 4 µm step size), for 16 hr in 20 min intervals at 37°C, 5% CO<sub>2</sub>. Images were processed using Photoshop, ImageJ, or Imaris.</p></sec><sec id="s4-14"><title>Proliferation assays</title><p>Proliferation rates were determined using the CellTiter Glo (Promega) luminescent cell viability assay, according to the manufacturer instructions. Cells were seeded at an initial density of 5000 or 10,000 cells/well (98 well plate), in triplicate or quadruplicate wells, and experiments were repeated at least three independent times. An unpaired two-tailed <italic>t</italic>-test was used to compare significance between groups.</p></sec><sec id="s4-15"><title>ChIP-seq tumor sample preparation and sequencing</title><p>ChIP-seq was performed as previously described (<xref ref-type="bibr" rid="bib45">Lee et al., 2006</xref>). Zebrafish were euthanized on ice and melanomas were excised, finely minced using a scalpel blade in 5 ml cold PBS in a petri dish, transferred to a 50 ml Falcon tube, and the petri dish was rinsed once with 5 ml PBS. Tumor samples were cross-linked in 1:10 11% formaldehyde solution for 10 min at RT, with occasional gentle mixing. Formaldehyde was quenched by addition of 1:20 2.5M glycine. Next, the tumor suspension was mechanically homogenized on ice at the lowest setting for 30 s or until no large tumor chunks are visible and passed through a 100 μm filter into a new 50 ml Falcon tube. Cells were spun down at 2500 RPM for 15 min, washed twice with PBS, and pellets were flash frozen and stored at −80°C, or subjected to chromatin immunoprecipitation with anti-SATB2 (sc-81376, Santa Cruz), anti-Histone H3 acetyl K27 (ab4729, Abcam) or anti-Histone H3 tri methyl K9 (ab8898, Abcam) antibodies. Ten μl of input DNA and the entire volume of ChIP DNA samples were prepared for sequencing. Libraries were prepared using the NEBNext Multiplex Oligos Kit (18-cycle PCR enrichment step), mixed in equal quantities (2–10 nM), and run on an Illumina Hi-Seq2000.</p></sec><sec id="s4-16"><title>ChIP-sequencing bioinformatics</title><p>All ChIP-Seq datasets were aligned to build version danRer7 of the zebrafish genome using Bowtie2 (version 2.2.1) (<xref ref-type="bibr" rid="bib44">Langmead and Salzberg, 2012</xref>) with the following parameters: <monospace>--end-to-end</monospace>, -N0, -L20. We used the MACS2 version 2.1.0 (<xref ref-type="bibr" rid="bib100">Zhang et al., 2008</xref>) peak finding algorithm to identify regions of ChIP-Seq peaks, with a <italic>q</italic>-value threshold of enrichment of 0.05 for all datasets (<xref ref-type="bibr" rid="bib44">Langmead and Salzberg, 2012</xref>). Super enhancers were called using the ROSE package with the following parameters: -STITCHING_DISTANCE = 12.5, -TSS_EXCLUSION_ZONE_SIZE = 0. The H3K27Ac ChIP-Seq called peaks are used as enhancer gff input (<xref ref-type="bibr" rid="bib48">Lovén et al., 2013</xref>; <xref ref-type="bibr" rid="bib92">Whyte et al., 2013</xref>). Genome track images were generated using the UCSC browser. SATB2-bound loci were determined by overlapping all regions 3 kb upstream of the transcriptional start site (TSS), gene body (GB) and 3 kb downstream of the transcriptional end site (TES) of all transcripts in the danRer7 assembly, with all significantly bound SATB2-peaks (p&lt;10<sup>−7</sup>). SATB2-bound peaks were compared to SATB2 enhancers peaks to determine the SATB2-bound enhancers. GREAT (<xref ref-type="bibr" rid="bib29">Hiller et al., 2013</xref>) version 2.0.2 was used for GO-term enrichment analysis of SATB2-associated loci and SATB2-bound enhancers, using the ‘Basal plus extension’ genomic region association (proximal 10 kb upstream of TSS, 5 kb downstream of TSS, distal up to 100 kb) to associate genomic regions with nearby genes. The list of SATB2-bound genes was converted to human orthologs using DIOPT - DRSC Integrative Ortholog Prediction Tool (<xref ref-type="bibr" rid="bib30">Hu et al., 2011</xref>) returning only the best matching ortholog. Data sets are deposited to the GEO Gene Expression Omnibus, accession number GSE77923 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77923">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77923</ext-link>).</p></sec><sec id="s4-17"><title>RNA-sequencing bioinformatics</title><p>RNA-seq was performed on three biological replicates of primary zebrafish melanoma tumors that were excised from MCR:EGFP (control) and MCR:SATB2 overexpressing Tg<italic>(BRAF<sup>V600E</sup>);p53<sup>-/-</sup>; mitf<sup>-/-</sup></italic>zebrafish. Zebrafish were euthanized on ice, melanomas were isolated and mechanically homogenized in RTL buffer (Qiagen) containing β-mercaptoethanol. Tumor lysates were transferred onto a QiaShredder column (Qiagen), and RNA isolation was performed using the RNA Micro Plus kit (Qiagen) according to the manufacturers instruction. RNA quality was determined using a Nanodrop and Fragment Analyzer (Advanced Analytical). Total RNA was depleted of ribosomal RNA with the Ribo-Zero Gold kit (Epicentre). Ribosome-depleted RNA was used to create multiplexed RNA-seq libraries (NEBNext Ultra, NEB) according to manufacturer's instructions. Samples with an average DNA input size of 300 base pairs were sequenced on an Illumina Hi-Seq2000 sequencer with 2 × 100 bp paired-end reads. Quality control of RNA-Seq datasets was performed by FastQC29 and Cutadapt30 to remove adaptor sequences and low quality regions. The high-quality reads were aligned to UCSC build danRer7 of zebrafish genome using Tophat31 2.0.11 without novel splicing form calls. Transcript abundance and differential expression were calculated with Cufflinks32 2.2.1. FPKM values were used to normalize and quantify each transcript; the resulting list of differential expressed genes are filtered by log(2) fold change &gt;1.5 and a p-value&lt;0.05. Human orthologs were predicted using DIOPT33. Data sets are deposited to the GEO Gene Expression Omnibus accession number GSE77923. RNA-seq was performed on three biological replicates of SKMEL2 transduced with pINDUCER20-SATB2 after 48 hr of induction with 2 µg/mL of doxycycline as outlined above, except for the mechanical homogenization. Pathway analyses were conducted using GSEA (v4.0) (<xref ref-type="bibr" rid="bib82">Subramanian et al., 2005</xref>) and IPA (Qiagen). Pathway and gene list overlaps were plotted using BioVenn (<xref ref-type="bibr" rid="bib34">Hulsen et al., 2008</xref>).</p></sec><sec id="s4-18"><title>Statistics</title><p>Comparison of Kaplan-Meier survival curves was performed by a log-rank (Mantel-Cox) test. Statistical difference in qPCR expression analysis between large groups of MCR:EGFP and MCR:SATB2 primary tumors, and difference in estimated fraction of tumor propagating cells between MCR:EGFP and MCR:SATB2 donors were determined by an unpaired two-tailed Mann-Whitney test. The rest of the statistics were performed with an unpaired two-tailed t-test. An F-test was used to determine similar variation between compared groups. Graphs show the median with s.e.m. No statistical methods were used to predetermine sample size. Experiments to quantify proliferation by PH3 immunohistochemistry, and cells with degraded 488-conjungated gelatin were scored blindly. Irradiated Casper zebrafish were randomized between transplantation groups. All statistical analyses were performed with GraphPad Prism. NS, not significant, p&gt;0.05; *p≤0.05; **p≤0.01; ***p≤0.001; ****p≤0.0001.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Serine Avagyan and Alicia McConnell for helpful discussion, Elliott Hagedorn for helpful discussion and time-lapse imaging support, Cristine Lian for histopathology discussion, and Rachel Fogely for ChIP-seq guidance. MF was supported by Boehringer Ingelheim Fonds. EvR was supported by a Netherlands Organization for Scientific Research (NWO) Rubicon fellowship, and a Dutch Cancer Foundation (KWF) fellowship for Fundamental Cancer Research. LIZ is supported by: R01 CA103846, MRA (Zon, Garraway), The Starr Cancer Consortium and the Ellison Foundation.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf2"><p>Senior editor, <italic>eLife</italic></p></fn><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>LIZ is a founder and stockholder of Fate Therapeutics Inc, Scholar Rock Inc, Camp4 Therapeutics Inc, Amagma Therapeutics Inc, and a scientific advisor for Stemgent.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Resources, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Resources, Software, Formal analysis, Investigation, Visualization</p></fn><fn fn-type="con" id="con7"><p>Resources, Data curation, Software, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Investigation</p></fn><fn fn-type="con" id="con12"><p>Resources</p></fn><fn fn-type="con" id="con13"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con14"><p>Resources</p></fn><fn fn-type="con" id="con15"><p>Resources, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Zebrafish were maintained under IACUC-approved conditions (Boston Children's Hospital Institutional Animal Care and Use Committee protocol # 20-10-4253R).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Schematic of screened pools of epigenetic factors and source plasmid references.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64370-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Differential gene expression list of primary MCR:SATB2 vs MCR:EGFP tumors by RNA-seq (Sheet 1).</title><p>Genes confirmed by qPCR on a large panel of primary MCR:SATB2 tumors versus MCR:EGFP tumors. Red is upregulated, green is downregulated. (Sheet 2). Best human ortholog prediction with DIOPT (Sheet 3). MCR tumors RNA-seq data matched with human orthologs (Sheet 4). Input for GSEA analysis on MCR tumors (Sheet 5). Input for IPA analysis on MCR tumors (Sheet 6). SATB2 bound genes based on SATB2 ChIP-seq in MCR:SATB2 tumor (Sheet 7). DIOPT human ortholog prediction of SATB2 bound targets (Sheet 8), and humanized SATB2 bound target list (Sheet 9) used for overlap in Biovenn with published TFAP2A active targets in <xref ref-type="fig" rid="fig3">Figure 3D</xref>. Overlap of significant genes with with ChIP-seq to determine SATB2-bound and SATB2-associated loci that are misexpressed. (Sheet 10).</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64370-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>SATB2-associated genes that are neural crest related (Sheet 1) SATB2-associated genes, determined by using GREAT genomic region association ‘Basal plus extension’ (proximal 10 kb upstream of TSS, 5 kb downstream of TSS, distal up to 100 kb).</title><p>(Sheet 2) Neural-crest-associated genes. (Sheet 3) SATB2/neural-crest-associated genes. (Sheet 4) Human predicted orthologs (DIOPT) of SATB2-Bound genes (TSS+ gene body +/- 3 kb).</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64370-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>RNA-seq of SKMEL2 TetOn SATB2 48 hr +/- doxycycline.</title><p>(Sheet 1) Genes with a log(2) fold change &gt;1.0 and a p-value&lt;0.05. (Sheet 2) Unfiltered RNA-seq expression data.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64370-supp4-v2.xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>qRT-PCR primers.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64370-supp5-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-64370-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Data sets are deposited to the GEO Gene Expression Omnibus, accession number GSE77923.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Fazio</surname><given-names>M</given-names></name><name><surname>van Rooijen</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zon</surname><given-names>LI</given-names></name><name><surname>Fazio</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>SATB2 induces transcriptional programs in melanoma that lead to metastatic behavior</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77923">GSE77923</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ablain</surname> <given-names>J</given-names></name><name><surname>Durand</surname> <given-names>EM</given-names></name><name><surname>Yang</surname> <given-names>S</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A CRISPR/Cas9 vector system for tissue-specific gene disruption in zebrafish</article-title><source>Developmental Cell</source><volume>32</volume><fpage>756</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2015.01.032</pub-id><pub-id pub-id-type="pmid">25752963</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ablain</surname> <given-names>J</given-names></name><name><surname>Xu</surname> <given-names>M</given-names></name><name><surname>Rothschild</surname> <given-names>H</given-names></name><name><surname>Jordan</surname> <given-names>RC</given-names></name><name><surname>Mito</surname> <given-names>JK</given-names></name><name><surname>Daniels</surname> <given-names>BH</given-names></name><name><surname>Bell</surname> <given-names>CF</given-names></name><name><surname>Joseph</surname> <given-names>NM</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Bastian</surname> <given-names>BC</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name><name><surname>Yeh</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Human tumor genomics and zebrafish modeling identify <italic>SPRED1</italic> loss as a driver of mucosal melanoma</article-title><source>Science</source><volume>362</volume><fpage>1055</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1126/science.aau6509</pub-id><pub-id pub-id-type="pmid">30385465</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname> <given-names>F</given-names></name><name><surname>Haass</surname> <given-names>NK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Microenvironment-Driven dynamic heterogeneity and phenotypic plasticity as a mechanism of melanoma therapy resistance</article-title><source>Frontiers in Oncology</source><volume>8</volume><elocation-id>173</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2018.00173</pub-id><pub-id pub-id-type="pmid">29881716</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname> <given-names>HJ</given-names></name><name><surname>Park</surname> <given-names>Y</given-names></name><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Park</surname> <given-names>HC</given-names></name><name><surname>Seo</surname> <given-names>SK</given-names></name><name><surname>Yeo</surname> <given-names>SY</given-names></name><name><surname>Geum</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The expression profile and function of Satb2 in zebrafish embryonic development</article-title><source>Molecules and Cells</source><volume>30</volume><fpage>377</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1007/s10059-010-0128-6</pub-id><pub-id pub-id-type="pmid">20814748</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname> <given-names>CM</given-names></name><name><surname>Morrison</surname> <given-names>JA</given-names></name><name><surname>Kulesa</surname> <given-names>PM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Melanoma revives an embryonic migration program to promote plasticity and invasion</article-title><source>Pigment Cell &amp; Melanoma Research</source><volume>25</volume><fpage>573</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148X.2012.01025.x</pub-id><pub-id pub-id-type="pmid">22681858</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajpai</surname> <given-names>R</given-names></name><name><surname>Chen</surname> <given-names>DA</given-names></name><name><surname>Rada-Iglesias</surname> <given-names>A</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Xiong</surname> <given-names>Y</given-names></name><name><surname>Helms</surname> <given-names>J</given-names></name><name><surname>Chang</surname> <given-names>CP</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Swigut</surname> <given-names>T</given-names></name><name><surname>Wysocka</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CHD7 cooperates with PBAF to control multipotent neural crest formation</article-title><source>Nature</source><volume>463</volume><fpage>958</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1038/nature08733</pub-id><pub-id pub-id-type="pmid">20130577</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betancur</surname> <given-names>P</given-names></name><name><surname>Bronner-Fraser</surname> <given-names>M</given-names></name><name><surname>Sauka-Spengler</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Assembling neural crest regulatory circuits into a gene regulatory network</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>26</volume><fpage>581</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.042308.113245</pub-id><pub-id pub-id-type="pmid">19575671</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birkeland</surname> <given-names>E</given-names></name><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Poduval</surname> <given-names>D</given-names></name><name><surname>Geisler</surname> <given-names>J</given-names></name><name><surname>Nakken</surname> <given-names>S</given-names></name><name><surname>Vodak</surname> <given-names>D</given-names></name><name><surname>Meza-Zepeda</surname> <given-names>LA</given-names></name><name><surname>Hovig</surname> <given-names>E</given-names></name><name><surname>Myklebost</surname> <given-names>O</given-names></name><name><surname>Knappskog</surname> <given-names>S</given-names></name><name><surname>Lønning</surname> <given-names>PE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Patterns of genomic evolution in advanced melanoma</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2665</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05063-1</pub-id><pub-id pub-id-type="pmid">29991680</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boshuizen</surname> <given-names>J</given-names></name><name><surname>Vredevoogd</surname> <given-names>DW</given-names></name><name><surname>Krijgsman</surname> <given-names>O</given-names></name><name><surname>Ligtenberg</surname> <given-names>MA</given-names></name><name><surname>Blankenstein</surname> <given-names>S</given-names></name><name><surname>de Bruijn</surname> <given-names>B</given-names></name><name><surname>Frederick</surname> <given-names>DT</given-names></name><name><surname>Kenski</surname> <given-names>JCN</given-names></name><name><surname>Parren</surname> <given-names>M</given-names></name><name><surname>Brüggemann</surname> <given-names>M</given-names></name><name><surname>Madu</surname> <given-names>MF</given-names></name><name><surname>Rozeman</surname> <given-names>EA</given-names></name><name><surname>Song</surname> <given-names>JY</given-names></name><name><surname>Horlings</surname> <given-names>HM</given-names></name><name><surname>Blank</surname> <given-names>CU</given-names></name><name><surname>van Akkooi</surname> <given-names>ACJ</given-names></name><name><surname>Flaherty</surname> <given-names>KT</given-names></name><name><surname>Boland</surname> <given-names>GM</given-names></name><name><surname>Peeper</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Reversal of pre-existing NGFR-driven tumor and immune therapy resistance</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3946</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17739-8</pub-id><pub-id pub-id-type="pmid">32770055</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boumahdi</surname> <given-names>S</given-names></name><name><surname>de Sauvage</surname> <given-names>FJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The great escape: tumour cell plasticity in resistance to targeted therapy</article-title><source>Nature Reviews Drug Discovery</source><volume>19</volume><fpage>39</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0044-1</pub-id><pub-id pub-id-type="pmid">31601994</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Network</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Genomic classification of cutaneous melanoma</article-title><source>Cell</source><volume>161</volume><fpage>1681</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.044</pub-id><pub-id pub-id-type="pmid">26091043</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceol</surname> <given-names>CJ</given-names></name><name><surname>Houvras</surname> <given-names>Y</given-names></name><name><surname>Jane-Valbuena</surname> <given-names>J</given-names></name><name><surname>Bilodeau</surname> <given-names>S</given-names></name><name><surname>Orlando</surname> <given-names>DA</given-names></name><name><surname>Battisti</surname> <given-names>V</given-names></name><name><surname>Fritsch</surname> <given-names>L</given-names></name><name><surname>Lin</surname> <given-names>WM</given-names></name><name><surname>Hollmann</surname> <given-names>TJ</given-names></name><name><surname>Ferré</surname> <given-names>F</given-names></name><name><surname>Bourque</surname> <given-names>C</given-names></name><name><surname>Burke</surname> <given-names>CJ</given-names></name><name><surname>Turner</surname> <given-names>L</given-names></name><name><surname>Uong</surname> <given-names>A</given-names></name><name><surname>Johnson</surname> <given-names>LA</given-names></name><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Mermel</surname> <given-names>CH</given-names></name><name><surname>Loda</surname> <given-names>M</given-names></name><name><surname>Ait-Si-Ali</surname> <given-names>S</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Young</surname> <given-names>RA</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset</article-title><source>Nature</source><volume>471</volume><fpage>513</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/nature09806</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charbonneau</surname> <given-names>M</given-names></name><name><surname>Lavoie</surname> <given-names>RR</given-names></name><name><surname>Lauzier</surname> <given-names>A</given-names></name><name><surname>Harper</surname> <given-names>K</given-names></name><name><surname>McDonald</surname> <given-names>PP</given-names></name><name><surname>Dubois</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Platelet-Derived growth factor receptor activation promotes the prodestructive Invadosome-Forming phenotype of synoviocytes from patients with rheumatoid arthritis</article-title><source>The Journal of Immunology</source><volume>196</volume><fpage>3264</fpage><lpage>3275</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1500502</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czerwinska</surname> <given-names>P</given-names></name><name><surname>Jaworska</surname> <given-names>AM</given-names></name><name><surname>Wlodarczyk</surname> <given-names>NA</given-names></name><name><surname>Mackiewicz</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Melanoma stem Cell-Like phenotype and significant suppression of immune response within a tumor are regulated by TRIM28 protein</article-title><source>Cancers</source><volume>12</volume><elocation-id>2998</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12102998</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname> <given-names>M</given-names></name><name><surname>Henderson</surname> <given-names>RE</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Long-term drug administration in the adult zebrafish using oral gavage for Cancer preclinical studies</article-title><source>Disease Models &amp; Mechanisms</source><volume>9</volume><fpage>811</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1242/dmm.024166</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Kim</surname> <given-names>M</given-names></name><name><surname>Kanchi</surname> <given-names>KL</given-names></name><name><surname>Dees</surname> <given-names>ND</given-names></name><name><surname>Lu</surname> <given-names>C</given-names></name><name><surname>Griffith</surname> <given-names>M</given-names></name><name><surname>Fenstermacher</surname> <given-names>D</given-names></name><name><surname>Sung</surname> <given-names>H</given-names></name><name><surname>Miller</surname> <given-names>CA</given-names></name><name><surname>Goetz</surname> <given-names>B</given-names></name><name><surname>Wendl</surname> <given-names>MC</given-names></name><name><surname>Griffith</surname> <given-names>O</given-names></name><name><surname>Cornelius</surname> <given-names>LA</given-names></name><name><surname>Linette</surname> <given-names>GP</given-names></name><name><surname>McMichael</surname> <given-names>JF</given-names></name><name><surname>Sondak</surname> <given-names>VK</given-names></name><name><surname>Fields</surname> <given-names>RC</given-names></name><name><surname>Ley</surname> <given-names>TJ</given-names></name><name><surname>Mulé</surname> <given-names>JJ</given-names></name><name><surname>Wilson</surname> <given-names>RK</given-names></name><name><surname>Weber</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clonal architectures and driver mutations in metastatic melanomas</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e111153</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0111153</pub-id><pub-id pub-id-type="pmid">25393105</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekpe-Adewuyi</surname> <given-names>E</given-names></name><name><surname>Lopez-Campistrous</surname> <given-names>A</given-names></name><name><surname>Tang</surname> <given-names>X</given-names></name><name><surname>Brindley</surname> <given-names>DN</given-names></name><name><surname>McMullen</surname> <given-names>TP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid Cancer by driving the epithelial-mesenchymal transition</article-title><source>Oncotarget</source><volume>7</volume><fpage>83684</fpage><lpage>83700</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.13299</pub-id><pub-id pub-id-type="pmid">27845909</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallahi-Sichani</surname> <given-names>M</given-names></name><name><surname>Becker</surname> <given-names>V</given-names></name><name><surname>Izar</surname> <given-names>B</given-names></name><name><surname>Baker</surname> <given-names>GJ</given-names></name><name><surname>Lin</surname> <given-names>JR</given-names></name><name><surname>Boswell</surname> <given-names>SA</given-names></name><name><surname>Shah</surname> <given-names>P</given-names></name><name><surname>Rotem</surname> <given-names>A</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Sorger</surname> <given-names>PK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state</article-title><source>Molecular Systems Biology</source><volume>13</volume><elocation-id>905</elocation-id><pub-id pub-id-type="doi">10.15252/msb.20166796</pub-id><pub-id pub-id-type="pmid">28069687</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazio</surname> <given-names>M</given-names></name><name><surname>Rooijen</surname> <given-names>E</given-names></name><name><surname>Mito</surname> <given-names>JK</given-names></name><name><surname>Modhurima</surname> <given-names>R</given-names></name><name><surname>Weiskopf</surname> <given-names>E</given-names></name><name><surname>Yang</surname> <given-names>S</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Recurrent co‐alteration of HDGF and SETDB1 on chromosome 1q drives cutaneous melanoma progression and poor prognosis</article-title><source>Pigment Cell &amp; Melanoma Research</source><volume>63</volume><elocation-id>pcmr.12937</elocation-id><pub-id pub-id-type="doi">10.1111/pcmr.12937</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Wan</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Jiang</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Large-scale public data reuse to model immunotherapy response and resistance</article-title><source>Genome Medicine</source><volume>12</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-020-0721-z</pub-id><pub-id pub-id-type="pmid">32102694</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagnon</surname> <given-names>JA</given-names></name><name><surname>Valen</surname> <given-names>E</given-names></name><name><surname>Thyme</surname> <given-names>SB</given-names></name><name><surname>Huang</surname> <given-names>P</given-names></name><name><surname>Ahkmetova</surname> <given-names>L</given-names></name><name><surname>Pauli</surname> <given-names>A</given-names></name><name><surname>Montague</surname> <given-names>TG</given-names></name><name><surname>Zimmerman</surname> <given-names>S</given-names></name><name><surname>Richter</surname> <given-names>C</given-names></name><name><surname>Schier</surname> <given-names>AF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Efficient mutagenesis by Cas9 Protein-Mediated oligonucleotide insertion and Large-Scale assessment of Single-Guide RNAs</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e98186</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0098186</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname> <given-names>X</given-names></name><name><surname>Jiang</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>D</given-names></name><name><surname>Liao</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SATB2 induces stem-like properties and promotes epithelial-mesenchymal transition in hepatocellular carcinoma</article-title><source>International Journal of Clinical and Experimental Pathology</source><volume>10</volume><fpage>11932</fpage><lpage>11940</lpage><pub-id pub-id-type="pmid">31966558</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Aksoy</surname> <given-names>BA</given-names></name><name><surname>Dogrusoz</surname> <given-names>U</given-names></name><name><surname>Dresdner</surname> <given-names>G</given-names></name><name><surname>Gross</surname> <given-names>B</given-names></name><name><surname>Sumer</surname> <given-names>SO</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Jacobsen</surname> <given-names>A</given-names></name><name><surname>Sinha</surname> <given-names>R</given-names></name><name><surname>Larsson</surname> <given-names>E</given-names></name><name><surname>Cerami</surname> <given-names>E</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>pl1</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id><pub-id pub-id-type="pmid">23550210</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubelmann</surname> <given-names>C</given-names></name><name><surname>Gattiker</surname> <given-names>A</given-names></name><name><surname>Massouras</surname> <given-names>A</given-names></name><name><surname>Hens</surname> <given-names>K</given-names></name><name><surname>David</surname> <given-names>F</given-names></name><name><surname>Decouttere</surname> <given-names>F</given-names></name><name><surname>Rougemont</surname> <given-names>J</given-names></name><name><surname>Deplancke</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>GETPrime: a gene- or transcript-specific primer database for quantitative real-time PCR</article-title><source>Database</source><volume>2011</volume><elocation-id>bar040</elocation-id><pub-id pub-id-type="doi">10.1093/database/bar040</pub-id><pub-id pub-id-type="pmid">21917859</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname> <given-names>PB</given-names></name><name><surname>Kuperwasser</surname> <given-names>C</given-names></name><name><surname>Brunet</surname> <given-names>JP</given-names></name><name><surname>Ramaswamy</surname> <given-names>S</given-names></name><name><surname>Kuo</surname> <given-names>WL</given-names></name><name><surname>Gray</surname> <given-names>JW</given-names></name><name><surname>Naber</surname> <given-names>SP</given-names></name><name><surname>Weinberg</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The melanocyte differentiation program predisposes to metastasis after neoplastic transformation</article-title><source>Nature Genetics</source><volume>37</volume><fpage>1047</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1038/ng1634</pub-id><pub-id pub-id-type="pmid">16142232</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gyorgy</surname> <given-names>AB</given-names></name><name><surname>Szemes</surname> <given-names>M</given-names></name><name><surname>de Juan Romero</surname> <given-names>C</given-names></name><name><surname>Tarabykin</surname> <given-names>V</given-names></name><name><surname>Agoston</surname> <given-names>DV</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>SATB2 interacts with chromatin-remodeling molecules in differentiating cortical neurons</article-title><source>European Journal of Neuroscience</source><volume>27</volume><fpage>865</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.2008.06061.x</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname> <given-names>MQ</given-names></name><name><surname>Gordon</surname> <given-names>JA</given-names></name><name><surname>Beloti</surname> <given-names>MM</given-names></name><name><surname>Croce</surname> <given-names>CM</given-names></name><name><surname>van Wijnen</surname> <given-names>AJ</given-names></name><name><surname>Stein</surname> <given-names>JL</given-names></name><name><surname>Stein</surname> <given-names>GS</given-names></name><name><surname>Lian</surname> <given-names>JB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A network connecting Runx2, SATB2, and the miR-23a~27a~24-2 cluster regulates the osteoblast differentiation program</article-title><source>PNAS</source><volume>107</volume><fpage>19879</fpage><lpage>19884</lpage><pub-id pub-id-type="doi">10.1073/pnas.1007698107</pub-id><pub-id pub-id-type="pmid">20980664</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heilmann</surname> <given-names>S</given-names></name><name><surname>Ratnakumar</surname> <given-names>K</given-names></name><name><surname>Langdon</surname> <given-names>E</given-names></name><name><surname>Kansler</surname> <given-names>E</given-names></name><name><surname>Kim</surname> <given-names>I</given-names></name><name><surname>Campbell</surname> <given-names>NR</given-names></name><name><surname>Perry</surname> <given-names>E</given-names></name><name><surname>McMahon</surname> <given-names>A</given-names></name><name><surname>Kaufman</surname> <given-names>C</given-names></name><name><surname>van Rooijen</surname> <given-names>E</given-names></name><name><surname>Lee</surname> <given-names>W</given-names></name><name><surname>Iacobuzio-Donahue</surname> <given-names>C</given-names></name><name><surname>Hynes</surname> <given-names>R</given-names></name><name><surname>Zon</surname> <given-names>L</given-names></name><name><surname>Xavier</surname> <given-names>J</given-names></name><name><surname>White</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A quantitative system for studying metastasis using transparent zebrafish</article-title><source>Cancer Research</source><volume>75</volume><fpage>4272</fpage><lpage>4282</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-3319</pub-id><pub-id pub-id-type="pmid">26282170</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiller</surname> <given-names>M</given-names></name><name><surname>Agarwal</surname> <given-names>S</given-names></name><name><surname>Notwell</surname> <given-names>JH</given-names></name><name><surname>Parikh</surname> <given-names>R</given-names></name><name><surname>Guturu</surname> <given-names>H</given-names></name><name><surname>Wenger</surname> <given-names>AM</given-names></name><name><surname>Bejerano</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Computational methods to detect conserved non-genic elements in phylogenetically isolated genomes: application to zebrafish</article-title><source>Nucleic Acids Research</source><volume>41</volume><elocation-id>e151</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkt557</pub-id><pub-id pub-id-type="pmid">23814184</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Flockhart</surname> <given-names>I</given-names></name><name><surname>Vinayagam</surname> <given-names>A</given-names></name><name><surname>Bergwitz</surname> <given-names>C</given-names></name><name><surname>Berger</surname> <given-names>B</given-names></name><name><surname>Perrimon</surname> <given-names>N</given-names></name><name><surname>Mohr</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>An integrative approach to ortholog prediction for disease-focused and other functional studies</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>357</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-357</pub-id><pub-id pub-id-type="pmid">21880147</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays</article-title><source>Journal of Immunological Methods</source><volume>347</volume><fpage>70</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2009.06.008</pub-id><pub-id pub-id-type="pmid">19567251</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hugo</surname> <given-names>W</given-names></name><name><surname>Shi</surname> <given-names>H</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name><name><surname>Piva</surname> <given-names>M</given-names></name><name><surname>Song</surname> <given-names>C</given-names></name><name><surname>Kong</surname> <given-names>X</given-names></name><name><surname>Moriceau</surname> <given-names>G</given-names></name><name><surname>Hong</surname> <given-names>A</given-names></name><name><surname>Dahlman</surname> <given-names>KB</given-names></name><name><surname>Johnson</surname> <given-names>DB</given-names></name><name><surname>Sosman</surname> <given-names>JA</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><name><surname>Lo</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Non-genomic and immune evolution of melanoma acquiring MAPKi resistance</article-title><source>Cell</source><volume>162</volume><fpage>1271</fpage><lpage>1285</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.07.061</pub-id><pub-id pub-id-type="pmid">26359985</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hugo</surname> <given-names>W</given-names></name><name><surname>Zaretsky</surname> <given-names>JM</given-names></name><name><surname>Sun</surname> <given-names>L</given-names></name><name><surname>Song</surname> <given-names>C</given-names></name><name><surname>Moreno</surname> <given-names>BH</given-names></name><name><surname>Hu-Lieskovan</surname> <given-names>S</given-names></name><name><surname>Berent-Maoz</surname> <given-names>B</given-names></name><name><surname>Pang</surname> <given-names>J</given-names></name><name><surname>Chmielowski</surname> <given-names>B</given-names></name><name><surname>Cherry</surname> <given-names>G</given-names></name><name><surname>Seja</surname> <given-names>E</given-names></name><name><surname>Lomeli</surname> <given-names>S</given-names></name><name><surname>Kong</surname> <given-names>X</given-names></name><name><surname>Kelley</surname> <given-names>MC</given-names></name><name><surname>Sosman</surname> <given-names>JA</given-names></name><name><surname>Johnson</surname> <given-names>DB</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><name><surname>Lo</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma</article-title><source>Cell</source><volume>165</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.02.065</pub-id><pub-id pub-id-type="pmid">26997480</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulsen</surname> <given-names>T</given-names></name><name><surname>de Vlieg</surname> <given-names>J</given-names></name><name><surname>Alkema</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>BioVenn - a web application for the comparison and visualization of biological lists using area-proportional venn diagrams</article-title><source>BMC Genomics</source><volume>9</volume><elocation-id>488</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-9-488</pub-id><pub-id pub-id-type="pmid">18925949</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Pan-cancer analysis of whole genomes</article-title><source>Nature</source><volume>578</volume><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1969-6</pub-id><pub-id pub-id-type="pmid">32025007</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwanaga</surname> <given-names>R</given-names></name><name><surname>Truong</surname> <given-names>BT</given-names></name><name><surname>Hsu</surname> <given-names>JY</given-names></name><name><surname>Lambert</surname> <given-names>KA</given-names></name><name><surname>Vyas</surname> <given-names>R</given-names></name><name><surname>Orlicky</surname> <given-names>D</given-names></name><name><surname>Shellman</surname> <given-names>YG</given-names></name><name><surname>Tan</surname> <given-names>AC</given-names></name><name><surname>Ceol</surname> <given-names>C</given-names></name><name><surname>Artinger</surname> <given-names>KB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Loss of prdm1a accelerates melanoma onset and progression</article-title><source>Molecular Carcinogenesis</source><volume>59</volume><fpage>1052</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1002/mc.23236</pub-id><pub-id pub-id-type="pmid">32562448</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jao</surname> <given-names>LE</given-names></name><name><surname>Wente</surname> <given-names>SR</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system</article-title><source>PNAS</source><volume>110</volume><fpage>13904</fpage><lpage>13909</lpage><pub-id pub-id-type="doi">10.1073/pnas.1308335110</pub-id><pub-id pub-id-type="pmid">23918387</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannessen</surname> <given-names>CM</given-names></name><name><surname>Johnson</surname> <given-names>LA</given-names></name><name><surname>Piccioni</surname> <given-names>F</given-names></name><name><surname>Townes</surname> <given-names>A</given-names></name><name><surname>Frederick</surname> <given-names>DT</given-names></name><name><surname>Donahue</surname> <given-names>MK</given-names></name><name><surname>Narayan</surname> <given-names>R</given-names></name><name><surname>Flaherty</surname> <given-names>KT</given-names></name><name><surname>Wargo</surname> <given-names>JA</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A melanocyte lineage program confers resistance to MAP kinase pathway inhibition</article-title><source>Nature</source><volume>504</volume><fpage>138</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1038/nature12688</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapp</surname> <given-names>FG</given-names></name><name><surname>Perlin</surname> <given-names>JR</given-names></name><name><surname>Hagedorn</surname> <given-names>EJ</given-names></name><name><surname>Gansner</surname> <given-names>JM</given-names></name><name><surname>Schwarz</surname> <given-names>DE</given-names></name><name><surname>O'Connell</surname> <given-names>LA</given-names></name><name><surname>Johnson</surname> <given-names>NS</given-names></name><name><surname>Amemiya</surname> <given-names>C</given-names></name><name><surname>Fisher</surname> <given-names>DE</given-names></name><name><surname>Wölfle</surname> <given-names>U</given-names></name><name><surname>Trompouki</surname> <given-names>E</given-names></name><name><surname>Niemeyer</surname> <given-names>CM</given-names></name><name><surname>Driever</surname> <given-names>W</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Protection from UV light is an evolutionarily conserved feature of the haematopoietic niche</article-title><source>Nature</source><volume>558</volume><fpage>445</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0213-0</pub-id><pub-id pub-id-type="pmid">29899448</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname> <given-names>CK</given-names></name><name><surname>Mosimann</surname> <given-names>C</given-names></name><name><surname>Fan</surname> <given-names>ZP</given-names></name><name><surname>Yang</surname> <given-names>S</given-names></name><name><surname>Thomas</surname> <given-names>AJ</given-names></name><name><surname>Ablain</surname> <given-names>J</given-names></name><name><surname>Tan</surname> <given-names>JL</given-names></name><name><surname>Fogley</surname> <given-names>RD</given-names></name><name><surname>van Rooijen</surname> <given-names>E</given-names></name><name><surname>Hagedorn</surname> <given-names>EJ</given-names></name><name><surname>Ciarlo</surname> <given-names>C</given-names></name><name><surname>White</surname> <given-names>RM</given-names></name><name><surname>Matos</surname> <given-names>DA</given-names></name><name><surname>Puller</surname> <given-names>AC</given-names></name><name><surname>Santoriello</surname> <given-names>C</given-names></name><name><surname>Liao</surname> <given-names>EC</given-names></name><name><surname>Young</surname> <given-names>RA</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation</article-title><source>Science</source><volume>351</volume><elocation-id>aad2197</elocation-id><pub-id pub-id-type="doi">10.1126/science.aad2197</pub-id><pub-id pub-id-type="pmid">26823433</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikuiri</surname> <given-names>T</given-names></name><name><surname>Mishima</surname> <given-names>H</given-names></name><name><surname>Imura</surname> <given-names>H</given-names></name><name><surname>Suzuki</surname> <given-names>S</given-names></name><name><surname>Matsuzawa</surname> <given-names>Y</given-names></name><name><surname>Nakamura</surname> <given-names>T</given-names></name><name><surname>Fukumoto</surname> <given-names>S</given-names></name><name><surname>Yoshimura</surname> <given-names>Y</given-names></name><name><surname>Watanabe</surname> <given-names>S</given-names></name><name><surname>Kinoshita</surname> <given-names>A</given-names></name><name><surname>Yamada</surname> <given-names>T</given-names></name><name><surname>Shindoh</surname> <given-names>M</given-names></name><name><surname>Sugita</surname> <given-names>Y</given-names></name><name><surname>Maeda</surname> <given-names>H</given-names></name><name><surname>Yawaka</surname> <given-names>Y</given-names></name><name><surname>Mikoya</surname> <given-names>T</given-names></name><name><surname>Natsume</surname> <given-names>N</given-names></name><name><surname>Yoshiura</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Patients with SATB2-associated syndrome exhibiting multiple odontomas</article-title><source>American Journal of Medical Genetics Part A</source><volume>176</volume><fpage>2614</fpage><lpage>2622</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.40670</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>HJ</given-names></name><name><surname>Lee</surname> <given-names>HJ</given-names></name><name><surname>Kim</surname> <given-names>H</given-names></name><name><surname>Cho</surname> <given-names>SW</given-names></name><name><surname>Kim</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly</article-title><source>Genome Research</source><volume>19</volume><fpage>1279</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1101/gr.089417.108</pub-id><pub-id pub-id-type="pmid">19470664</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutner</surname> <given-names>RH</given-names></name><name><surname>Zhang</surname> <given-names>XY</given-names></name><name><surname>Reiser</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors</article-title><source>Nature Protocols</source><volume>4</volume><fpage>495</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.22</pub-id><pub-id pub-id-type="pmid">19300443</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname> <given-names>B</given-names></name><name><surname>Salzberg</surname> <given-names>SL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fast gapped-read alignment with bowtie 2</article-title><source>Nature Methods</source><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>TI</given-names></name><name><surname>Johnstone</surname> <given-names>SE</given-names></name><name><surname>Young</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Chromatin immunoprecipitation and microarray-based analysis of protein location</article-title><source>Nature Protocols</source><volume>1</volume><fpage>729</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.98</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>White</surname> <given-names>RM</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Transplantation in zebrafish</article-title><source>Methods in Cell Biology</source><volume>105</volume><fpage>403</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-381320-6.00017-5</pub-id><pub-id pub-id-type="pmid">21951540</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>FZ</given-names></name><name><surname>Dhillon</surname> <given-names>AS</given-names></name><name><surname>Anderson</surname> <given-names>RL</given-names></name><name><surname>McArthur</surname> <given-names>G</given-names></name><name><surname>Ferrao</surname> <given-names>PT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Phenotype switching in melanoma: implications for progression and therapy</article-title><source>Frontiers in Oncology</source><volume>5</volume><elocation-id>31</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2015.00031</pub-id><pub-id pub-id-type="pmid">25763355</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovén</surname> <given-names>J</given-names></name><name><surname>Hoke</surname> <given-names>HA</given-names></name><name><surname>Lin</surname> <given-names>CY</given-names></name><name><surname>Lau</surname> <given-names>A</given-names></name><name><surname>Orlando</surname> <given-names>DA</given-names></name><name><surname>Vakoc</surname> <given-names>CR</given-names></name><name><surname>Bradner</surname> <given-names>JE</given-names></name><name><surname>Lee</surname> <given-names>TI</given-names></name><name><surname>Young</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Selective inhibition of tumor oncogenes by disruption of super-enhancers</article-title><source>Cell</source><volume>153</volume><fpage>320</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.036</pub-id><pub-id pub-id-type="pmid">23582323</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maheswaran</surname> <given-names>S</given-names></name><name><surname>Haber</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cell fate: transition loses its invasive edge</article-title><source>Nature</source><volume>527</volume><fpage>452</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1038/nature16313</pub-id><pub-id pub-id-type="pmid">26560026</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansour</surname> <given-names>MA</given-names></name><name><surname>Asano</surname> <given-names>E</given-names></name><name><surname>Hyodo</surname> <given-names>T</given-names></name><name><surname>Akter</surname> <given-names>KA</given-names></name><name><surname>Takahashi</surname> <given-names>M</given-names></name><name><surname>Hamaguchi</surname> <given-names>M</given-names></name><name><surname>Senga</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Special AT-rich sequence-binding protein 2 suppresses invadopodia formation in HCT116 cells via palladin inhibition</article-title><source>Experimental Cell Research</source><volume>332</volume><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2014.12.003</pub-id><pub-id pub-id-type="pmid">25523619</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marine</surname> <given-names>JC</given-names></name><name><surname>Dawson</surname> <given-names>SJ</given-names></name><name><surname>Dawson</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Non-genetic mechanisms of therapeutic resistance in Cancer</article-title><source>Nature Reviews Cancer</source><volume>20</volume><fpage>743</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1038/s41568-020-00302-4</pub-id><pub-id pub-id-type="pmid">33033407</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>KH</given-names></name><name><surname>Hayes</surname> <given-names>KE</given-names></name><name><surname>Walk</surname> <given-names>EL</given-names></name><name><surname>Ammer</surname> <given-names>AG</given-names></name><name><surname>Markwell</surname> <given-names>SM</given-names></name><name><surname>Weed</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Quantitative measurement of Invadopodia-mediated extracellular matrix proteolysis in single and multicellular contexts</article-title><source>Journal of Visualized Experiments</source><volume>66</volume><elocation-id>e4119</elocation-id><pub-id pub-id-type="doi">10.3791/4119</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayor</surname> <given-names>R</given-names></name><name><surname>Theveneau</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The neural crest</article-title><source>Development</source><volume>140</volume><fpage>2247</fpage><lpage>2251</lpage><pub-id pub-id-type="doi">10.1242/dev.091751</pub-id><pub-id pub-id-type="pmid">23674598</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConnell</surname> <given-names>AM</given-names></name><name><surname>Mito</surname> <given-names>JK</given-names></name><name><surname>Ablain</surname> <given-names>J</given-names></name><name><surname>Dang</surname> <given-names>M</given-names></name><name><surname>Formichella</surname> <given-names>L</given-names></name><name><surname>Fisher</surname> <given-names>DE</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Neural crest state activation in NRAS driven melanoma, but not in NRAS-driven melanocyte expansion</article-title><source>Developmental Biology</source><volume>449</volume><fpage>107</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2018.05.026</pub-id><pub-id pub-id-type="pmid">29883661</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname> <given-names>WL</given-names></name><name><surname>Ortiz-Londono</surname> <given-names>CF</given-names></name><name><surname>Mathew</surname> <given-names>TK</given-names></name><name><surname>Hoang</surname> <given-names>K</given-names></name><name><surname>Katzman</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mutual regulation between Satb2 and Fezf2 promotes subcerebral projection neuron identity in the developing cerebral cortex</article-title><source>PNAS</source><volume>112</volume><fpage>11702</fpage><lpage>11707</lpage><pub-id pub-id-type="doi">10.1073/pnas.1504144112</pub-id><pub-id pub-id-type="pmid">26324926</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meerbrey</surname> <given-names>KL</given-names></name><name><surname>Hu</surname> <given-names>G</given-names></name><name><surname>Kessler</surname> <given-names>JD</given-names></name><name><surname>Roarty</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>MZ</given-names></name><name><surname>Fang</surname> <given-names>JE</given-names></name><name><surname>Herschkowitz</surname> <given-names>JI</given-names></name><name><surname>Burrows</surname> <given-names>AE</given-names></name><name><surname>Ciccia</surname> <given-names>A</given-names></name><name><surname>Sun</surname> <given-names>T</given-names></name><name><surname>Schmitt</surname> <given-names>EM</given-names></name><name><surname>Bernardi</surname> <given-names>RJ</given-names></name><name><surname>Fu</surname> <given-names>X</given-names></name><name><surname>Bland</surname> <given-names>CS</given-names></name><name><surname>Cooper</surname> <given-names>TA</given-names></name><name><surname>Schiff</surname> <given-names>R</given-names></name><name><surname>Rosen</surname> <given-names>JM</given-names></name><name><surname>Westbrook</surname> <given-names>TF</given-names></name><name><surname>Elledge</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo</article-title><source>PNAS</source><volume>108</volume><fpage>3665</fpage><lpage>3670</lpage><pub-id pub-id-type="doi">10.1073/pnas.1019736108</pub-id><pub-id pub-id-type="pmid">21307310</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname> <given-names>J</given-names></name><name><surname>Krijgsman</surname> <given-names>O</given-names></name><name><surname>Tsoi</surname> <given-names>J</given-names></name><name><surname>Robert</surname> <given-names>L</given-names></name><name><surname>Hugo</surname> <given-names>W</given-names></name><name><surname>Song</surname> <given-names>C</given-names></name><name><surname>Kong</surname> <given-names>X</given-names></name><name><surname>Possik</surname> <given-names>PA</given-names></name><name><surname>Cornelissen-Steijger</surname> <given-names>PD</given-names></name><name><surname>Geukes Foppen</surname> <given-names>MH</given-names></name><name><surname>Kemper</surname> <given-names>K</given-names></name><name><surname>Goding</surname> <given-names>CR</given-names></name><name><surname>McDermott</surname> <given-names>U</given-names></name><name><surname>Blank</surname> <given-names>C</given-names></name><name><surname>Haanen</surname> <given-names>J</given-names></name><name><surname>Graeber</surname> <given-names>TG</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><name><surname>Lo</surname> <given-names>RS</given-names></name><name><surname>Peeper</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>5712</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms6712</pub-id><pub-id pub-id-type="pmid">25502142</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname> <given-names>DA</given-names></name><name><surname>Diaz</surname> <given-names>B</given-names></name><name><surname>Bromann</surname> <given-names>PA</given-names></name><name><surname>Tsai</surname> <given-names>JH</given-names></name><name><surname>Kawakami</surname> <given-names>Y</given-names></name><name><surname>Maurer</surname> <given-names>J</given-names></name><name><surname>Stewart</surname> <given-names>RA</given-names></name><name><surname>Izpisúa-Belmonte</surname> <given-names>JC</given-names></name><name><surname>Courtneidge</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A Src-Tks5 pathway is required for neural crest cell migration during embryonic development</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e22499</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0022499</pub-id><pub-id pub-id-type="pmid">21799874</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname> <given-names>DA</given-names></name><name><surname>Courtneidge</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>12</volume><fpage>413</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1038/nrm3141</pub-id><pub-id pub-id-type="pmid">21697900</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naik</surname> <given-names>R</given-names></name><name><surname>Galande</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>SATB family chromatin organizers as master regulators of tumor progression</article-title><source>Oncogene</source><volume>38</volume><fpage>1989</fpage><lpage>2004</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0541-4</pub-id><pub-id pub-id-type="pmid">30413763</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanni</surname> <given-names>P</given-names></name><name><surname>Landuzzi</surname> <given-names>L</given-names></name><name><surname>Manara</surname> <given-names>MC</given-names></name><name><surname>Righi</surname> <given-names>A</given-names></name><name><surname>Nicoletti</surname> <given-names>G</given-names></name><name><surname>Cristalli</surname> <given-names>C</given-names></name><name><surname>Pasello</surname> <given-names>M</given-names></name><name><surname>Parra</surname> <given-names>A</given-names></name><name><surname>Carrabotta</surname> <given-names>M</given-names></name><name><surname>Ferracin</surname> <given-names>M</given-names></name><name><surname>Palladini</surname> <given-names>A</given-names></name><name><surname>Ianzano</surname> <given-names>ML</given-names></name><name><surname>Giusti</surname> <given-names>V</given-names></name><name><surname>Ruzzi</surname> <given-names>F</given-names></name><name><surname>Magnani</surname> <given-names>M</given-names></name><name><surname>Donati</surname> <given-names>DM</given-names></name><name><surname>Picci</surname> <given-names>P</given-names></name><name><surname>Lollini</surname> <given-names>PL</given-names></name><name><surname>Scotlandi</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>12174</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-48634-y</pub-id><pub-id pub-id-type="pmid">31434953</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayak</surname> <given-names>RC</given-names></name><name><surname>Hegde</surname> <given-names>S</given-names></name><name><surname>Althoff</surname> <given-names>MJ</given-names></name><name><surname>Wellendorf</surname> <given-names>AM</given-names></name><name><surname>Mohmoud</surname> <given-names>F</given-names></name><name><surname>Perentesis</surname> <given-names>J</given-names></name><name><surname>Reina-Campos</surname> <given-names>M</given-names></name><name><surname>Reynaud</surname> <given-names>D</given-names></name><name><surname>Zheng</surname> <given-names>Y</given-names></name><name><surname>Diaz-Meco</surname> <given-names>MT</given-names></name><name><surname>Moscat</surname> <given-names>J</given-names></name><name><surname>Cancelas</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The signaling Axis atypical protein kinase C λ/ι-Satb2 mediates leukemic transformation of B-cell progenitors</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>46</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-07846-y</pub-id><pub-id pub-id-type="pmid">30610188</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazarian</surname> <given-names>R</given-names></name><name><surname>Shi</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Kong</surname> <given-names>X</given-names></name><name><surname>Koya</surname> <given-names>RC</given-names></name><name><surname>Lee</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Lee</surname> <given-names>MK</given-names></name><name><surname>Attar</surname> <given-names>N</given-names></name><name><surname>Sazegar</surname> <given-names>H</given-names></name><name><surname>Chodon</surname> <given-names>T</given-names></name><name><surname>Nelson</surname> <given-names>SF</given-names></name><name><surname>McArthur</surname> <given-names>G</given-names></name><name><surname>Sosman</surname> <given-names>JA</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><name><surname>Lo</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation</article-title><source>Nature</source><volume>468</volume><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1038/nature09626</pub-id><pub-id pub-id-type="pmid">21107323</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname> <given-names>MA</given-names></name><name><surname>Huang</surname> <given-names>RY</given-names></name><name><surname>Jackson</surname> <given-names>RA</given-names></name><name><surname>Thiery</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>EMT: 2016</article-title><source>Cell</source><volume>166</volume><fpage>21</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.06.028</pub-id><pub-id pub-id-type="pmid">27368099</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuno</surname> <given-names>H</given-names></name><name><surname>Renault Mihara</surname> <given-names>F</given-names></name><name><surname>Ohta</surname> <given-names>S</given-names></name><name><surname>Fukuda</surname> <given-names>K</given-names></name><name><surname>Kurosawa</surname> <given-names>K</given-names></name><name><surname>Akamatsu</surname> <given-names>W</given-names></name><name><surname>Sanosaka</surname> <given-names>T</given-names></name><name><surname>Kohyama</surname> <given-names>J</given-names></name><name><surname>Hayashi</surname> <given-names>K</given-names></name><name><surname>Nakajima</surname> <given-names>K</given-names></name><name><surname>Takahashi</surname> <given-names>T</given-names></name><name><surname>Wysocka</surname> <given-names>J</given-names></name><name><surname>Kosaki</surname> <given-names>K</given-names></name><name><surname>Okano</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CHARGE syndrome modeling using patient-iPSCs reveals defective migration of neural crest cells harboring CHD7 mutations</article-title><source>eLife</source><volume>6</volume><elocation-id>e21114</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.21114</pub-id><pub-id pub-id-type="pmid">29179815</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patton</surname> <given-names>EE</given-names></name><name><surname>Widlund</surname> <given-names>HR</given-names></name><name><surname>Kutok</surname> <given-names>JL</given-names></name><name><surname>Kopani</surname> <given-names>KR</given-names></name><name><surname>Amatruda</surname> <given-names>JF</given-names></name><name><surname>Murphey</surname> <given-names>RD</given-names></name><name><surname>Berghmans</surname> <given-names>S</given-names></name><name><surname>Mayhall</surname> <given-names>EA</given-names></name><name><surname>Traver</surname> <given-names>D</given-names></name><name><surname>Fletcher</surname> <given-names>CD</given-names></name><name><surname>Aster</surname> <given-names>JC</given-names></name><name><surname>Granter</surname> <given-names>SR</given-names></name><name><surname>Look</surname> <given-names>AT</given-names></name><name><surname>Lee</surname> <given-names>C</given-names></name><name><surname>Fisher</surname> <given-names>DE</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma</article-title><source>Current Biology</source><volume>15</volume><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2005.01.031</pub-id><pub-id pub-id-type="pmid">15694309</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paz</surname> <given-names>H</given-names></name><name><surname>Pathak</surname> <given-names>N</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Invading one step at a time: the role of invadopodia in tumor metastasis</article-title><source>Oncogene</source><volume>33</volume><fpage>4193</fpage><lpage>4202</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.393</pub-id><pub-id pub-id-type="pmid">24077283</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez-Guijarro</surname> <given-names>E</given-names></name><name><surname>Day</surname> <given-names>C-P</given-names></name><name><surname>Merlino</surname> <given-names>G</given-names></name><name><surname>Zaidi</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genetically engineered mouse models of melanoma</article-title><source>Cancer</source><volume>123</volume><fpage>2089</fpage><lpage>2103</lpage><pub-id pub-id-type="doi">10.1002/cncr.30684</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priestley</surname> <given-names>P</given-names></name><name><surname>Baber</surname> <given-names>J</given-names></name><name><surname>Lolkema</surname> <given-names>MP</given-names></name><name><surname>Steeghs</surname> <given-names>N</given-names></name><name><surname>de Bruijn</surname> <given-names>E</given-names></name><name><surname>Shale</surname> <given-names>C</given-names></name><name><surname>Duyvesteyn</surname> <given-names>K</given-names></name><name><surname>Haidari</surname> <given-names>S</given-names></name><name><surname>van Hoeck</surname> <given-names>A</given-names></name><name><surname>Onstenk</surname> <given-names>W</given-names></name><name><surname>Roepman</surname> <given-names>P</given-names></name><name><surname>Voda</surname> <given-names>M</given-names></name><name><surname>Bloemendal</surname> <given-names>HJ</given-names></name><name><surname>Tjan-Heijnen</surname> <given-names>VCG</given-names></name><name><surname>van Herpen</surname> <given-names>CML</given-names></name><name><surname>Labots</surname> <given-names>M</given-names></name><name><surname>Witteveen</surname> <given-names>PO</given-names></name><name><surname>Smit</surname> <given-names>EF</given-names></name><name><surname>Sleijfer</surname> <given-names>S</given-names></name><name><surname>Voest</surname> <given-names>EE</given-names></name><name><surname>Cuppen</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pan-cancer whole-genome analyses of metastatic solid tumours</article-title><source>Nature</source><volume>575</volume><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1689-y</pub-id><pub-id pub-id-type="pmid">31645765</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintavalle</surname> <given-names>M</given-names></name><name><surname>Elia</surname> <given-names>L</given-names></name><name><surname>Condorelli</surname> <given-names>G</given-names></name><name><surname>Courtneidge</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro</article-title><source>Journal of Cell Biology</source><volume>189</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1083/jcb.200912096</pub-id><pub-id pub-id-type="pmid">20351064</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rainger</surname> <given-names>JK</given-names></name><name><surname>Bhatia</surname> <given-names>S</given-names></name><name><surname>Bengani</surname> <given-names>H</given-names></name><name><surname>Gautier</surname> <given-names>P</given-names></name><name><surname>Rainger</surname> <given-names>J</given-names></name><name><surname>Pearson</surname> <given-names>M</given-names></name><name><surname>Ansari</surname> <given-names>M</given-names></name><name><surname>Crow</surname> <given-names>J</given-names></name><name><surname>Mehendale</surname> <given-names>F</given-names></name><name><surname>Palinkasova</surname> <given-names>B</given-names></name><name><surname>Dixon</surname> <given-names>MJ</given-names></name><name><surname>Thompson</surname> <given-names>PJ</given-names></name><name><surname>Matarin</surname> <given-names>M</given-names></name><name><surname>Sisodiya</surname> <given-names>SM</given-names></name><name><surname>Kleinjan</surname> <given-names>DA</given-names></name><name><surname>Fitzpatrick</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Disruption of SATB2 or its long-range cis-regulation by SOX9 causes a syndromic form of pierre Robin sequence</article-title><source>Human Molecular Genetics</source><volume>23</volume><fpage>2569</fpage><lpage>2579</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddt647</pub-id><pub-id pub-id-type="pmid">24363063</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rambow</surname> <given-names>F</given-names></name><name><surname>Rogiers</surname> <given-names>A</given-names></name><name><surname>Marin-Bejar</surname> <given-names>O</given-names></name><name><surname>Aibar</surname> <given-names>S</given-names></name><name><surname>Femel</surname> <given-names>J</given-names></name><name><surname>Dewaele</surname> <given-names>M</given-names></name><name><surname>Karras</surname> <given-names>P</given-names></name><name><surname>Brown</surname> <given-names>D</given-names></name><name><surname>Chang</surname> <given-names>YH</given-names></name><name><surname>Debiec-Rychter</surname> <given-names>M</given-names></name><name><surname>Adriaens</surname> <given-names>C</given-names></name><name><surname>Radaelli</surname> <given-names>E</given-names></name><name><surname>Wolter</surname> <given-names>P</given-names></name><name><surname>Bechter</surname> <given-names>O</given-names></name><name><surname>Dummer</surname> <given-names>R</given-names></name><name><surname>Levesque</surname> <given-names>M</given-names></name><name><surname>Piris</surname> <given-names>A</given-names></name><name><surname>Frederick</surname> <given-names>DT</given-names></name><name><surname>Boland</surname> <given-names>G</given-names></name><name><surname>Flaherty</surname> <given-names>KT</given-names></name><name><surname>van den Oord</surname> <given-names>J</given-names></name><name><surname>Voet</surname> <given-names>T</given-names></name><name><surname>Aerts</surname> <given-names>S</given-names></name><name><surname>Lund</surname> <given-names>AW</given-names></name><name><surname>Marine</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Toward minimal residual Disease-Directed therapy in melanoma</article-title><source>Cell</source><volume>174</volume><fpage>843</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.06.025</pub-id><pub-id pub-id-type="pmid">30017245</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebecca</surname> <given-names>VW</given-names></name><name><surname>Wood</surname> <given-names>E</given-names></name><name><surname>Fedorenko</surname> <given-names>IV</given-names></name><name><surname>Paraiso</surname> <given-names>KH</given-names></name><name><surname>Haarberg</surname> <given-names>HE</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Xiang</surname> <given-names>Y</given-names></name><name><surname>Sarnaik</surname> <given-names>A</given-names></name><name><surname>Gibney</surname> <given-names>GT</given-names></name><name><surname>Sondak</surname> <given-names>VK</given-names></name><name><surname>Koomen</surname> <given-names>JM</given-names></name><name><surname>Smalley</surname> <given-names>KS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Evaluating melanoma drug response and therapeutic escape with quantitative proteomics</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>13</volume><fpage>1844</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.1074/mcp.M113.037424</pub-id><pub-id pub-id-type="pmid">24760959</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarese</surname> <given-names>F</given-names></name><name><surname>Dávila</surname> <given-names>A</given-names></name><name><surname>Nechanitzky</surname> <given-names>R</given-names></name><name><surname>De La Rosa-Velazquez</surname> <given-names>I</given-names></name><name><surname>Pereira</surname> <given-names>CF</given-names></name><name><surname>Engelke</surname> <given-names>R</given-names></name><name><surname>Takahashi</surname> <given-names>K</given-names></name><name><surname>Jenuwein</surname> <given-names>T</given-names></name><name><surname>Kohwi-Shigematsu</surname> <given-names>T</given-names></name><name><surname>Fisher</surname> <given-names>AG</given-names></name><name><surname>Grosschedl</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Satb1 and Satb2 regulate embryonic stem cell differentiation and nanog expression</article-title><source>Genes &amp; Development</source><volume>23</volume><fpage>2625</fpage><lpage>2638</lpage><pub-id pub-id-type="doi">10.1101/gad.1815709</pub-id><pub-id pub-id-type="pmid">19933152</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname> <given-names>Y</given-names></name><name><surname>Wehner</surname> <given-names>P</given-names></name><name><surname>Opitz</surname> <given-names>L</given-names></name><name><surname>Salinas-Riester</surname> <given-names>G</given-names></name><name><surname>Bongers</surname> <given-names>EM</given-names></name><name><surname>van Ravenswaaij-Arts</surname> <given-names>CM</given-names></name><name><surname>Wincent</surname> <given-names>J</given-names></name><name><surname>Schoumans</surname> <given-names>J</given-names></name><name><surname>Kohlhase</surname> <given-names>J</given-names></name><name><surname>Borchers</surname> <given-names>A</given-names></name><name><surname>Pauli</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CHD7, the gene mutated in CHARGE syndrome, regulates genes involved in neural crest cell guidance</article-title><source>Human Genetics</source><volume>133</volume><fpage>997</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1007/s00439-014-1444-2</pub-id><pub-id pub-id-type="pmid">24728844</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shain</surname> <given-names>AH</given-names></name><name><surname>Yeh</surname> <given-names>I</given-names></name><name><surname>Kovalyshyn</surname> <given-names>I</given-names></name><name><surname>Sriharan</surname> <given-names>A</given-names></name><name><surname>Talevich</surname> <given-names>E</given-names></name><name><surname>Gagnon</surname> <given-names>A</given-names></name><name><surname>Dummer</surname> <given-names>R</given-names></name><name><surname>North</surname> <given-names>J</given-names></name><name><surname>Pincus</surname> <given-names>L</given-names></name><name><surname>Ruben</surname> <given-names>B</given-names></name><name><surname>Rickaby</surname> <given-names>W</given-names></name><name><surname>D'Arrigo</surname> <given-names>C</given-names></name><name><surname>Robson</surname> <given-names>A</given-names></name><name><surname>Bastian</surname> <given-names>BC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The genetic evolution of melanoma from precursor lesions</article-title><source>New England Journal of Medicine</source><volume>373</volume><fpage>1926</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1502583</pub-id><pub-id pub-id-type="pmid">26559571</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan-Rooney</surname> <given-names>K</given-names></name><name><surname>Pálinkášová</surname> <given-names>B</given-names></name><name><surname>Eberhart</surname> <given-names>JK</given-names></name><name><surname>Dixon</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A cross-species analysis of Satb2 expression suggests deep conservation across vertebrate lineages</article-title><source>Developmental Dynamics</source><volume>239</volume><fpage>3481</fpage><lpage>3491</lpage><pub-id pub-id-type="doi">10.1002/dvdy.22483</pub-id><pub-id pub-id-type="pmid">21089028</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan-Rooney</surname> <given-names>K</given-names></name><name><surname>Swartz</surname> <given-names>ME</given-names></name><name><surname>Lovely</surname> <given-names>CB</given-names></name><name><surname>Dixon</surname> <given-names>MJ</given-names></name><name><surname>Eberhart</surname> <given-names>JK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Bmp and shh signaling mediate the expression of satb2 in the pharyngeal arches</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e59533</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0059533</pub-id><pub-id pub-id-type="pmid">23555697</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinmyo</surname> <given-names>Y</given-names></name><name><surname>Kawasaki</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CRISPR/Cas9‐Mediated gene knockout in the mouse brain using in utero electroporation</article-title><source>Current Protocols in Neuroscience</source><volume>79</volume><fpage>3.32.1</fpage><lpage>3.32.3</lpage><pub-id pub-id-type="doi">10.1002/cpns.26</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirley</surname> <given-names>SH</given-names></name><name><surname>Greene</surname> <given-names>VR</given-names></name><name><surname>Duncan</surname> <given-names>LM</given-names></name><name><surname>Torres Cabala</surname> <given-names>CA</given-names></name><name><surname>Grimm</surname> <given-names>EA</given-names></name><name><surname>Kusewitt</surname> <given-names>DF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Slug expression during melanoma progression</article-title><source>The American Journal of Pathology</source><volume>180</volume><fpage>2479</fpage><lpage>2489</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2012.02.014</pub-id><pub-id pub-id-type="pmid">22503751</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname> <given-names>A</given-names></name><name><surname>Makarov</surname> <given-names>V</given-names></name><name><surname>Merghoub</surname> <given-names>T</given-names></name><name><surname>Yuan</surname> <given-names>J</given-names></name><name><surname>Zaretsky</surname> <given-names>JM</given-names></name><name><surname>Desrichard</surname> <given-names>A</given-names></name><name><surname>Walsh</surname> <given-names>LA</given-names></name><name><surname>Postow</surname> <given-names>MA</given-names></name><name><surname>Wong</surname> <given-names>P</given-names></name><name><surname>Ho</surname> <given-names>TS</given-names></name><name><surname>Hollmann</surname> <given-names>TJ</given-names></name><name><surname>Bruggeman</surname> <given-names>C</given-names></name><name><surname>Kannan</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Elipenahli</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Harbison</surname> <given-names>CT</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Ribas</surname> <given-names>A</given-names></name><name><surname>Wolchok</surname> <given-names>JD</given-names></name><name><surname>Chan</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genetic basis for clinical response to CTLA-4 blockade in melanoma</article-title><source>New England Journal of Medicine</source><volume>371</volume><fpage>2189</fpage><lpage>2199</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1406498</pub-id><pub-id pub-id-type="pmid">25409260</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Gillette</surname> <given-names>MA</given-names></name><name><surname>Paulovich</surname> <given-names>A</given-names></name><name><surname>Pomeroy</surname> <given-names>SL</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>JL</given-names></name><name><surname>Fogley</surname> <given-names>RD</given-names></name><name><surname>Flynn</surname> <given-names>RA</given-names></name><name><surname>Ablain</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>S</given-names></name><name><surname>Saint-André</surname> <given-names>V</given-names></name><name><surname>Fan</surname> <given-names>ZP</given-names></name><name><surname>Do</surname> <given-names>BT</given-names></name><name><surname>Laga</surname> <given-names>AC</given-names></name><name><surname>Fujinaga</surname> <given-names>K</given-names></name><name><surname>Santoriello</surname> <given-names>C</given-names></name><name><surname>Greer</surname> <given-names>CB</given-names></name><name><surname>Kim</surname> <given-names>YJ</given-names></name><name><surname>Clohessy</surname> <given-names>JG</given-names></name><name><surname>Bothmer</surname> <given-names>A</given-names></name><name><surname>Pandell</surname> <given-names>N</given-names></name><name><surname>Avagyan</surname> <given-names>S</given-names></name><name><surname>Brogie</surname> <given-names>JE</given-names></name><name><surname>van Rooijen</surname> <given-names>E</given-names></name><name><surname>Hagedorn</surname> <given-names>EJ</given-names></name><name><surname>Shyh-Chang</surname> <given-names>N</given-names></name><name><surname>White</surname> <given-names>RM</given-names></name><name><surname>Price</surname> <given-names>DH</given-names></name><name><surname>Pandolfi</surname> <given-names>PP</given-names></name><name><surname>Peterlin</surname> <given-names>BM</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Kim</surname> <given-names>TH</given-names></name><name><surname>Asara</surname> <given-names>JM</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name><name><surname>Young</surname> <given-names>RA</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Stress from nucleotide depletion activates the transcriptional regulator HEXIM1 to suppress melanoma</article-title><source>Molecular Cell</source><volume>62</volume><fpage>34</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.03.013</pub-id><pub-id pub-id-type="pmid">27058786</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tirosh</surname> <given-names>I</given-names></name><name><surname>Izar</surname> <given-names>B</given-names></name><name><surname>Prakadan</surname> <given-names>SM</given-names></name><name><surname>Wadsworth</surname> <given-names>MH</given-names></name><name><surname>Treacy</surname> <given-names>D</given-names></name><name><surname>Rotem</surname> <given-names>A</given-names></name><name><surname>Rodman</surname> <given-names>C</given-names></name><name><surname>Lian</surname> <given-names>C</given-names></name><name><surname>Murphy</surname> <given-names>G</given-names></name><name><surname>Fallahi-Sichani</surname> <given-names>M</given-names></name><name><surname>Dutton-Regester</surname> <given-names>K</given-names></name><name><surname>Lin</surname> <given-names>JR</given-names></name><name><surname>Cohen</surname> <given-names>O</given-names></name><name><surname>Shah</surname> <given-names>P</given-names></name><name><surname>Lu</surname> <given-names>D</given-names></name><name><surname>Genshaft</surname> <given-names>AS</given-names></name><name><surname>Hughes</surname> <given-names>TK</given-names></name><name><surname>Ziegler</surname> <given-names>CG</given-names></name><name><surname>Kazer</surname> <given-names>SW</given-names></name><name><surname>Gaillard</surname> <given-names>A</given-names></name><name><surname>Kolb</surname> <given-names>KE</given-names></name><name><surname>Villani</surname> <given-names>AC</given-names></name><name><surname>Johannessen</surname> <given-names>CM</given-names></name><name><surname>Andreev</surname> <given-names>AY</given-names></name><name><surname>Van Allen</surname> <given-names>EM</given-names></name><name><surname>Bertagnolli</surname> <given-names>M</given-names></name><name><surname>Sorger</surname> <given-names>PK</given-names></name><name><surname>Sullivan</surname> <given-names>RJ</given-names></name><name><surname>Flaherty</surname> <given-names>KT</given-names></name><name><surname>Frederick</surname> <given-names>DT</given-names></name><name><surname>Jané-Valbuena</surname> <given-names>J</given-names></name><name><surname>Yoon</surname> <given-names>CH</given-names></name><name><surname>Rozenblatt-Rosen</surname> <given-names>O</given-names></name><name><surname>Shalek</surname> <given-names>AK</given-names></name><name><surname>Regev</surname> <given-names>A</given-names></name><name><surname>Regev</surname> <given-names>A</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq</article-title><source>Science</source><volume>352</volume><fpage>189</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1126/science.aad0501</pub-id><pub-id pub-id-type="pmid">27124452</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Allen</surname> <given-names>EM</given-names></name><name><surname>Wagle</surname> <given-names>N</given-names></name><name><surname>Sucker</surname> <given-names>A</given-names></name><name><surname>Treacy</surname> <given-names>DJ</given-names></name><name><surname>Johannessen</surname> <given-names>CM</given-names></name><name><surname>Goetz</surname> <given-names>EM</given-names></name><name><surname>Place</surname> <given-names>CS</given-names></name><name><surname>Taylor-Weiner</surname> <given-names>A</given-names></name><name><surname>Whittaker</surname> <given-names>S</given-names></name><name><surname>Kryukov</surname> <given-names>GV</given-names></name><name><surname>Hodis</surname> <given-names>E</given-names></name><name><surname>Rosenberg</surname> <given-names>M</given-names></name><name><surname>McKenna</surname> <given-names>A</given-names></name><name><surname>Cibulskis</surname> <given-names>K</given-names></name><name><surname>Farlow</surname> <given-names>D</given-names></name><name><surname>Zimmer</surname> <given-names>L</given-names></name><name><surname>Hillen</surname> <given-names>U</given-names></name><name><surname>Gutzmer</surname> <given-names>R</given-names></name><name><surname>Goldinger</surname> <given-names>SM</given-names></name><name><surname>Ugurel</surname> <given-names>S</given-names></name><name><surname>Gogas</surname> <given-names>HJ</given-names></name><name><surname>Egberts</surname> <given-names>F</given-names></name><name><surname>Berking</surname> <given-names>C</given-names></name><name><surname>Trefzer</surname> <given-names>U</given-names></name><name><surname>Loquai</surname> <given-names>C</given-names></name><name><surname>Weide</surname> <given-names>B</given-names></name><name><surname>Hassel</surname> <given-names>JC</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Carter</surname> <given-names>SL</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Schadendorf</surname> <given-names>D</given-names></name><collab>Dermatologic Cooperative Oncology Group of Germany (DeCOG)</collab></person-group><year iso-8601-date="2014">2014</year><article-title>The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma</article-title><source>Cancer Discovery</source><volume>4</volume><fpage>94</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0617</pub-id><pub-id pub-id-type="pmid">24265153</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Allen</surname> <given-names>EM</given-names></name><name><surname>Miao</surname> <given-names>D</given-names></name><name><surname>Schilling</surname> <given-names>B</given-names></name><name><surname>Shukla</surname> <given-names>SA</given-names></name><name><surname>Blank</surname> <given-names>C</given-names></name><name><surname>Zimmer</surname> <given-names>L</given-names></name><name><surname>Sucker</surname> <given-names>A</given-names></name><name><surname>Hillen</surname> <given-names>U</given-names></name><name><surname>Foppen</surname> <given-names>MHG</given-names></name><name><surname>Goldinger</surname> <given-names>SM</given-names></name><name><surname>Utikal</surname> <given-names>J</given-names></name><name><surname>Hassel</surname> <given-names>JC</given-names></name><name><surname>Weide</surname> <given-names>B</given-names></name><name><surname>Kaehler</surname> <given-names>KC</given-names></name><name><surname>Loquai</surname> <given-names>C</given-names></name><name><surname>Mohr</surname> <given-names>P</given-names></name><name><surname>Gutzmer</surname> <given-names>R</given-names></name><name><surname>Dummer</surname> <given-names>R</given-names></name><name><surname>Gabriel</surname> <given-names>S</given-names></name><name><surname>Wu</surname> <given-names>CJ</given-names></name><name><surname>Schadendorf</surname> <given-names>D</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genomic correlates of response to CTLA-4 blockade in metastatic melanoma</article-title><source>Science</source><volume>350</volume><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1126/science.aad0095</pub-id><pub-id pub-id-type="pmid">26359337</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Rooijen</surname> <given-names>E</given-names></name><name><surname>Fazio</surname> <given-names>M</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>From fish bowl to bedside: the power of zebrafish to unravel melanoma pathogenesis and discover new therapeutics</article-title><source>Pigment Cell &amp; Melanoma Research</source><volume>30</volume><fpage>402</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12592</pub-id><pub-id pub-id-type="pmid">28379616</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesan</surname> <given-names>AM</given-names></name><name><surname>Vyas</surname> <given-names>R</given-names></name><name><surname>Gramann</surname> <given-names>AK</given-names></name><name><surname>Dresser</surname> <given-names>K</given-names></name><name><surname>Gujja</surname> <given-names>S</given-names></name><name><surname>Bhatnagar</surname> <given-names>S</given-names></name><name><surname>Chhangawala</surname> <given-names>S</given-names></name><name><surname>Gomes</surname> <given-names>CBF</given-names></name><name><surname>Xi</surname> <given-names>HS</given-names></name><name><surname>Lian</surname> <given-names>CG</given-names></name><name><surname>Houvras</surname> <given-names>Y</given-names></name><name><surname>Edwards</surname> <given-names>YJK</given-names></name><name><surname>Deng</surname> <given-names>A</given-names></name><name><surname>Green</surname> <given-names>M</given-names></name><name><surname>Ceol</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma</article-title><source>Journal of Clinical Investigation</source><volume>128</volume><fpage>294</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1172/JCI92513</pub-id><pub-id pub-id-type="pmid">29202482</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verfaillie</surname> <given-names>A</given-names></name><name><surname>Imrichova</surname> <given-names>H</given-names></name><name><surname>Atak</surname> <given-names>ZK</given-names></name><name><surname>Dewaele</surname> <given-names>M</given-names></name><name><surname>Rambow</surname> <given-names>F</given-names></name><name><surname>Hulselmans</surname> <given-names>G</given-names></name><name><surname>Christiaens</surname> <given-names>V</given-names></name><name><surname>Svetlichnyy</surname> <given-names>D</given-names></name><name><surname>Luciani</surname> <given-names>F</given-names></name><name><surname>Van den Mooter</surname> <given-names>L</given-names></name><name><surname>Claerhout</surname> <given-names>S</given-names></name><name><surname>Fiers</surname> <given-names>M</given-names></name><name><surname>Journe</surname> <given-names>F</given-names></name><name><surname>Ghanem</surname> <given-names>GE</given-names></name><name><surname>Herrmann</surname> <given-names>C</given-names></name><name><surname>Halder</surname> <given-names>G</given-names></name><name><surname>Marine</surname> <given-names>JC</given-names></name><name><surname>Aerts</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6683</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7683</pub-id><pub-id pub-id-type="pmid">25865119</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y-Q</given-names></name><name><surname>Jiang</surname> <given-names>D-M</given-names></name><name><surname>Hu</surname> <given-names>S-S</given-names></name><name><surname>Zhao</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>M-H</given-names></name><name><surname>Ai</surname> <given-names>M-L</given-names></name><name><surname>Jiang</surname> <given-names>H-J</given-names></name><name><surname>Han</surname> <given-names>Y</given-names></name><name><surname>Ding</surname> <given-names>Y-Q</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>SATB2-AS1</italic> Suppresses Colorectal Carcinoma Aggressiveness by Inhibiting SATB2-Dependent <italic>Snail</italic> Transcription and Epithelial–Mesenchymal Transition</article-title><source>Cancer Research</source><volume>79</volume><fpage>3542</fpage><lpage>3556</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-2900</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname> <given-names>RM</given-names></name><name><surname>Sessa</surname> <given-names>A</given-names></name><name><surname>Burke</surname> <given-names>C</given-names></name><name><surname>Bowman</surname> <given-names>T</given-names></name><name><surname>LeBlanc</surname> <given-names>J</given-names></name><name><surname>Ceol</surname> <given-names>C</given-names></name><name><surname>Bourque</surname> <given-names>C</given-names></name><name><surname>Dovey</surname> <given-names>M</given-names></name><name><surname>Goessling</surname> <given-names>W</given-names></name><name><surname>Burns</surname> <given-names>CE</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transparent adult zebrafish as a tool for in vivo transplantation analysis</article-title><source>Cell Stem Cell</source><volume>2</volume><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2007.11.002</pub-id><pub-id pub-id-type="pmid">18371439</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whyte</surname> <given-names>WA</given-names></name><name><surname>Orlando</surname> <given-names>DA</given-names></name><name><surname>Hnisz</surname> <given-names>D</given-names></name><name><surname>Abraham</surname> <given-names>BJ</given-names></name><name><surname>Lin</surname> <given-names>CY</given-names></name><name><surname>Kagey</surname> <given-names>MH</given-names></name><name><surname>Rahl</surname> <given-names>PB</given-names></name><name><surname>Lee</surname> <given-names>TI</given-names></name><name><surname>Young</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Master transcription factors and mediator establish super-enhancers at key cell identity genes</article-title><source>Cell</source><volume>153</volume><fpage>307</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.035</pub-id><pub-id pub-id-type="pmid">23582322</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>F</given-names></name><name><surname>Jordan</surname> <given-names>A</given-names></name><name><surname>Kluz</surname> <given-names>T</given-names></name><name><surname>Shen</surname> <given-names>S</given-names></name><name><surname>Sun</surname> <given-names>H</given-names></name><name><surname>Cartularo</surname> <given-names>LA</given-names></name><name><surname>Costa</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>SATB2 expression increased anchorage-independent growth and cell migration in human bronchial epithelial cells</article-title><source>Toxicology and Applied Pharmacology</source><volume>293</volume><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2016.01.008</pub-id><pub-id pub-id-type="pmid">26780400</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>HY</given-names></name><name><surname>Fang</surname> <given-names>W</given-names></name><name><surname>Huang</surname> <given-names>ZW</given-names></name><name><surname>Lu</surname> <given-names>JC</given-names></name><name><surname>Wang</surname> <given-names>YQ</given-names></name><name><surname>Tang</surname> <given-names>QL</given-names></name><name><surname>Song</surname> <given-names>GH</given-names></name><name><surname>Kang</surname> <given-names>Y</given-names></name><name><surname>Zhu</surname> <given-names>XJ</given-names></name><name><surname>Zou</surname> <given-names>CY</given-names></name><name><surname>Yang</surname> <given-names>HL</given-names></name><name><surname>Shen</surname> <given-names>JN</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling</article-title><source>European Review for Medical and Pharmacological Sciences</source><volume>21</volume><fpage>4516</fpage><lpage>4528</lpage><pub-id pub-id-type="pmid">29131265</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname> <given-names>J</given-names></name><name><surname>White</surname> <given-names>RM</given-names></name><name><surname>Wedge</surname> <given-names>DC</given-names></name><name><surname>Van Loo</surname> <given-names>P</given-names></name><name><surname>de Ridder</surname> <given-names>J</given-names></name><name><surname>Capper</surname> <given-names>A</given-names></name><name><surname>Richardson</surname> <given-names>J</given-names></name><name><surname>Jones</surname> <given-names>D</given-names></name><name><surname>Raine</surname> <given-names>K</given-names></name><name><surname>Watson</surname> <given-names>IR</given-names></name><name><surname>Wu</surname> <given-names>CJ</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name><name><surname>Martincorena</surname> <given-names>I</given-names></name><name><surname>Nik-Zainal</surname> <given-names>S</given-names></name><name><surname>Mudie</surname> <given-names>L</given-names></name><name><surname>Moreau</surname> <given-names>Y</given-names></name><name><surname>Marshall</surname> <given-names>J</given-names></name><name><surname>Ramakrishna</surname> <given-names>M</given-names></name><name><surname>Tarpey</surname> <given-names>P</given-names></name><name><surname>Shlien</surname> <given-names>A</given-names></name><name><surname>Whitmore</surname> <given-names>I</given-names></name><name><surname>Gamble</surname> <given-names>S</given-names></name><name><surname>Latimer</surname> <given-names>C</given-names></name><name><surname>Langdon</surname> <given-names>E</given-names></name><name><surname>Kaufman</surname> <given-names>C</given-names></name><name><surname>Dovey</surname> <given-names>M</given-names></name><name><surname>Taylor</surname> <given-names>A</given-names></name><name><surname>Menzies</surname> <given-names>A</given-names></name><name><surname>McLaren</surname> <given-names>S</given-names></name><name><surname>O'Meara</surname> <given-names>S</given-names></name><name><surname>Butler</surname> <given-names>A</given-names></name><name><surname>Teague</surname> <given-names>J</given-names></name><name><surname>Lister</surname> <given-names>J</given-names></name><name><surname>Chin</surname> <given-names>L</given-names></name><name><surname>Campbell</surname> <given-names>P</given-names></name><name><surname>Adams</surname> <given-names>DJ</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name><name><surname>Patton</surname> <given-names>EE</given-names></name><name><surname>Stemple</surname> <given-names>DL</given-names></name><name><surname>Futreal</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models</article-title><source>Genome Biology</source><volume>14</volume><elocation-id>R113</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2013-14-10-r113</pub-id><pub-id pub-id-type="pmid">24148783</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>W</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name><name><surname>Ochoa</surname> <given-names>AC</given-names></name><name><surname>Shankar</surname> <given-names>S</given-names></name><name><surname>Srivastava</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Cellular transformation of human mammary epithelial cells by SATB2</article-title><source>Stem Cell Research</source><volume>19</volume><fpage>139</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.scr.2017.01.011</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>W</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name><name><surname>Shankar</surname> <given-names>S</given-names></name><name><surname>Srivastava</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>SATB2/β-catenin/TCF-LEF pathway induces cellular transformation by generating Cancer stem cells in colorectal Cancer</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>10939</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-05458-y</pub-id><pub-id pub-id-type="pmid">28887549</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarate</surname> <given-names>YA</given-names></name><name><surname>Bosanko</surname> <given-names>KA</given-names></name><name><surname>Caffrey</surname> <given-names>AR</given-names></name><name><surname>Bernstein</surname> <given-names>JA</given-names></name><name><surname>Martin</surname> <given-names>DM</given-names></name><name><surname>Williams</surname> <given-names>MS</given-names></name><name><surname>Berry-Kravis</surname> <given-names>EM</given-names></name><name><surname>Mark</surname> <given-names>PR</given-names></name><name><surname>Manning</surname> <given-names>MA</given-names></name><name><surname>Bhambhani</surname> <given-names>V</given-names></name><name><surname>Vargas</surname> <given-names>M</given-names></name><name><surname>Seeley</surname> <given-names>AH</given-names></name><name><surname>Estrada-Veras</surname> <given-names>JI</given-names></name><name><surname>van Dooren</surname> <given-names>MF</given-names></name><name><surname>Schwab</surname> <given-names>M</given-names></name><name><surname>Vanderver</surname> <given-names>A</given-names></name><name><surname>Melis</surname> <given-names>D</given-names></name><name><surname>Alsadah</surname> <given-names>A</given-names></name><name><surname>Sadler</surname> <given-names>L</given-names></name><name><surname>Van Esch</surname> <given-names>H</given-names></name><name><surname>Callewaert</surname> <given-names>B</given-names></name><name><surname>Oostra</surname> <given-names>A</given-names></name><name><surname>Maclean</surname> <given-names>J</given-names></name><name><surname>Dentici</surname> <given-names>ML</given-names></name><name><surname>Orlando</surname> <given-names>V</given-names></name><name><surname>Lipson</surname> <given-names>M</given-names></name><name><surname>Sparagana</surname> <given-names>SP</given-names></name><name><surname>Maarup</surname> <given-names>TJ</given-names></name><name><surname>Alsters</surname> <given-names>SI</given-names></name><name><surname>Brautbar</surname> <given-names>A</given-names></name><name><surname>Kovitch</surname> <given-names>E</given-names></name><name><surname>Naidu</surname> <given-names>S</given-names></name><name><surname>Lees</surname> <given-names>M</given-names></name><name><surname>Smith</surname> <given-names>DM</given-names></name><name><surname>Turner</surname> <given-names>L</given-names></name><name><surname>Raggio</surname> <given-names>V</given-names></name><name><surname>Spangenberg</surname> <given-names>L</given-names></name><name><surname>Garcia-Miñaúr</surname> <given-names>S</given-names></name><name><surname>Roeder</surname> <given-names>ER</given-names></name><name><surname>Littlejohn</surname> <given-names>RO</given-names></name><name><surname>Grange</surname> <given-names>D</given-names></name><name><surname>Pfotenhauer</surname> <given-names>J</given-names></name><name><surname>Jones</surname> <given-names>MC</given-names></name><name><surname>Balasubramanian</surname> <given-names>M</given-names></name><name><surname>Martinez-Monseny</surname> <given-names>A</given-names></name><name><surname>Blok</surname> <given-names>LS</given-names></name><name><surname>Gavrilova</surname> <given-names>R</given-names></name><name><surname>Fish</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mutation update for the SATB2 gene</article-title><source>Human Mutation</source><volume>40</volume><fpage>1013</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1002/humu.23771</pub-id><pub-id pub-id-type="pmid">31021519</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarate</surname> <given-names>YA</given-names></name><name><surname>Fish</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SATB2-associated syndrome: mechanisms, phenotype, and practical recommendations</article-title><source>American Journal of Medical Genetics Part A</source><volume>173</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.38022</pub-id><pub-id pub-id-type="pmid">27774744</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Meyer</surname> <given-names>CA</given-names></name><name><surname>Eeckhoute</surname> <given-names>J</given-names></name><name><surname>Johnson</surname> <given-names>DS</given-names></name><name><surname>Bernstein</surname> <given-names>BE</given-names></name><name><surname>Nusbaum</surname> <given-names>C</given-names></name><name><surname>Myers</surname> <given-names>RM</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Model-based analysis of ChIP-Seq (MACS)</article-title><source>Genome Biology</source><volume>9</volume><elocation-id>R137</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2008-9-9-r137</pub-id><pub-id pub-id-type="pmid">18798982</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>L-Q</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>W-T</given-names></name><name><surname>Yu</surname> <given-names>W</given-names></name><name><surname>Zhao</surname> <given-names>G-N</given-names></name><name><surname>Zhang</surname> <given-names>P</given-names></name><name><surname>Xiong</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Xue</surname> <given-names>Z</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Xie</surname> <given-names>X-M</given-names></name><name><surname>Guo</surname> <given-names>Z-C</given-names></name><name><surname>Lv</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>D-P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The AT-rich DNA-binding protein SATB2 promotes expression and physical association of human γ- and γ-Globin genes*</article-title><source>Journal of Biological Chemistry</source><volume>287</volume><fpage>30641</fpage><lpage>30652</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.355271</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>P</given-names></name><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Zhang</surname> <given-names>P</given-names></name><name><surname>Xu</surname> <given-names>R</given-names></name><name><surname>Ge</surname> <given-names>J</given-names></name><name><surname>Fu</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Ye</surname> <given-names>J</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>SATB2-Nanog Axis links age-related intrinsic changes of mesenchymal stem cells from craniofacial bone</article-title><source>Aging</source><volume>8</volume><fpage>2006</fpage><lpage>2022</lpage><pub-id pub-id-type="doi">10.18632/aging.101041</pub-id><pub-id pub-id-type="pmid">27632702</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64370.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>McArthur</surname><given-names>Grant</given-names></name><role>Reviewing Editor</role><aff><institution>Peter MacCallum Cancer Centre</institution><country>Australia</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>McArthur</surname><given-names>Grant</given-names> </name><role>Reviewer</role><aff><institution>Peter MacCallum Cancer Centre</institution><country>Australia</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Possik</surname><given-names>Patricia A</given-names></name><role>Reviewer</role><aff><institution>Instituto Nacional de Câncer (INCA)</institution><country>Brazil</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Cox</surname><given-names>Andrew G</given-names></name><role>Reviewer</role><aff><institution>Peter MacCallum Cancer Centre</institution><country>Australia</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Your manuscript using a powerful in vivo genetic system provides evidence that epigenetic regulators can be a driving force of malignant progression, specifically widespread metastatic disease. The data indicate relevance to human melanoma, both in disease progression and outcome and also in drug resistance.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;SATB2 induction of a neural crest mesenchyme-like program drives invasion and drug resistance in melanoma&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, including Grant McArthur as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Marianne Bronner as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Patricia A Possik (Reviewer #2); Andrew G Cox (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as <italic>eLife</italic> papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.</p><p>Summary:</p><p>The manuscript by Fazio, Van Rooijen and colleagues reports an in vivo screen for acceleration of melanoma development in the well characterized BRAF/p53 Zebrafish model. The authors identify the transcriptional regulator SATB2 in the screen and show that SATB2 regulates a network of genes that induce a neural crest stem cell like phenotype with enhanced invasion and metastases and an EMT phenotype. They show amplification of SATB2 in a subset of human melanomas and also demonstrate resistance to the BRAF-inhibitor vemurafenib in vivo. Previous studies from other investigators have shown a role for SATB2 in EMT, invasion and metastasis in various cancer models and correlated expression with clinical outcomes in human samples. The current manuscript demonstrates that SATB2 can drive, through epigenetic mechanisms, metastasis in cooperation with oncogenic drivers in an in vivo model that allows understanding of SATB2, and hence epigenetic mechanisms, in disease progression.</p><p>Essential revisions:</p><p>It is not clear in the allograft experiments presented in Figure 2F-I and Figure 2—figure supplement 1 use cells derived from single EGFP or SATB2 derived tumors. Please revise to clarify this point and if these data are representative of multiple tumors?</p><p>One of the main claims of the study is that SATB2 is involved in drug resistance. However, this claim is supported (robustly) only by the findings in zebrafish. Human melanomas are highly mutated and genetically heterogeneous. It would be important to discuss plans to extend these data into the human setting recognizing possible limitations of studying resistance purely in Zebrafish.</p><p>Regarding the overexpression screen: Although the authors focus on gene pools that accelerate the onset of melanoma, several pools show the opposite effect. In fact, Figure 1B gives the impression that most of the significant pools decrease the onset of melanoma formation. According to the figure legends, 6 pools were significant. The fact that the authors do not list which are the significant ones and do not discuss this in the text is curious. Is there a specific (technical) reason for not looking into genes that delay melanoma onset? Of course, there needs to be focus on one question and for this study, the authors chose to focus on genes with a positive effect on tumor progression, but it would be important to mention which other pools scored significantly and perhaps add some discussion on that. If other genes or pools were validated, it would be important to add that as well.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64370.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>It is not clear in the allograft experiments presented in Figure 2F-I and Figure 2—figure supplement 1 use cells derived from single EGFP or SATB2 derived tumors. Please revise to clarify this point and if these data are representative of multiple tumors?</p></disp-quote><p>The data shown is the combined result of multiple cohorts. Individual donor tumors (7 donors from MCR: SATB2 and 5 donors from MCR:EGFP) were transplanted into cohorts of 8-12 recipients. We have now further clarified this in the Results and figure legends.</p><p>Results:</p><p>“At the experimental end point at 3-3.5 weeks-post transplantation, 59.4%±2.3% (SEM; n=76 total recipients grafted from 7 individual donor tumors) of MCR:SATB2 transplants formed distant metastasis, compared to 21.8%±4.5% (SEM; n=37 total recipients grafted from 5 individual donor tumors) of EGFP-control transplants (<italic>p</italic>&lt;0.0001)”</p><p>Updated Figure 2 legend:</p><p>“(F) Pooled recipient data at the experimental end point at 3.5 weeks post-transplantation, 59.4%±2.3% (SEM; n=76 total recipients, grafted from 7 individual donor tumors) of MCR:SATB2 transplants formed distant metastasis, compared to 21.8 %±4.5% (SEM; n=37 total recipients grafted from 5 individual donor tumors) of EGFP-control transplants (<italic>p</italic>&lt;0.0001).”</p><p>Updated Figure 2—figure supplement 2 (former Supplementary Figure 5) legend:</p><p>“(D) Weekly prospective imaging of primary MCR:SATB2 individual tumor donor allograft in irradiated casper recipient. Arrows indicate distant metastasis from injection site. Related to Figure 2H.”</p><disp-quote content-type="editor-comment"><p>One of the main claims of the study is that SATB2 is involved in drug resistance. However, this claim is supported (robustly) only by the findings in zebrafish. Human melanomas are highly mutated and genetically heterogeneous. It would be important to discuss plans to extend these data into the human setting recognizing possible limitations of studying resistance purely in Zebrafish.</p></disp-quote><p>To address this point we have extended our discussion of the relation between our functional in vivo data on drug resistance in zebrafish and the Johannessen et al., 2013 study, which showed SATB2 overexpression as a primary hit from their resistance screen in vitro to induce resistance to BRAF inhibitor PLX4720 across 4 melanoma cell lines. We also highlighted the necessity of this cross-species validation of zebrafish data with human data since, as suggested by the reviewers, species conservation or pharmacokinetic differences between zebrafish and human might otherwise limit and/or confound conclusions on drug resistance studies.</p><p>Updated Discussion text:</p><p>“Interestingly, SATB2 has been reported as a primary hit in an unbiased overexpression screen for MAPK pathway inhibitor resistance drivers. [...] While genetic conservation and/or pharmacokinetic differences can limit the study of drug resistance in zebrafish, the cross-species phenotype conservation between our in vivo zebrafish data, together with the in vitro evidence in human melanoma cell lines from Johannssen and colleagues (Johannessen et al., 2013) validate SATB2 as driver of resistance to BRAF inhibition.”</p><p>“In summary, our work identifies SATB2 as a driver of invasion and resistance to Vemurafenib treatment in melanoma. Yet, further studies focused on the analysis of patient samples will be needed to assess the prevalence, and genetic/transcriptional context of SATB2 expression changes in targeted therapy and immunotherapy clinical settings. ”</p><disp-quote content-type="editor-comment"><p>Regarding the overexpression screen: Although the authors focus on gene pools that accelerate the onset of melanoma, several pools show the opposite effect. In fact, Figure 1B gives the impression that most of the significant pools decrease the onset of melanoma formation. According to the figure legends, 6 pools were significant. The fact that the authors do not list which are the significant ones and do not discuss this in the text is curious. Is there a specific (technical) reason for not looking into genes that delay melanoma onset? Of course, there needs to be focus on one question and for this study, the authors chose to focus on genes with a positive effect on tumor progression, but it would be important to mention which other pools scored significantly and perhaps add some discussion on that. If other genes or pools were validated, it would be important to add that as well.</p></disp-quote><p>We have now added a new supplementary figure (now Figure 1—figure supplement 1) showing single factor validation of 4 additional pools (3 positive and a negative pool for a total of 20 single factors). These show other significant accelerator hits from the screen (i.e. TRIM28, CDYL2, DMAP1, CBX5, PYGO2) that had all a much milder phenotype than SATB2. In addition, we show CBX3 as an example of a gene significantly delaying tumor onset compared to the EGFP control.</p><p>We have textually edited the Results section as follows:</p><p><italic>“</italic>We identified 6 significant candidate accelerator pools (Pool B,D,F,G,I,L vs. MCR:EGFP Logrank <italic>P</italic>&lt;0.0001****) of which Pool F had the strongest acceleration (Figure 1B), and tested individual factors from 4 accelerating pools (B/F/G/I) and a non significant pool (C) (Figure 1C and Figure 1—figure supplement 1A-D). […] We thus focused on further characterizing SATB2’s phenotype and investigating its mechanism of action.”</p><p>We did choose to focus on accelerators over genes delaying tumor onset both for biological interest, but also for various technical reasons. Namely (1) Studying delaying of onset would require a much longer follow up time (2) A screen for genes delaying onset might have more false negatives due to developmental toxicity, particularly since we are testing epigenetic/transcriptional regulators.</p><p>We edited the Discussion section to incorporate this point:</p><p>“This experimental approach can be used to identify pools/genes that can accelerate (e.g. SATB2 Figure 1C) or delay (e.g. CBX3 Figure 1—figure supplement 1D) tumor onset. […] Of the other 6 significant genes identified in the screen (TRIM28, CDYL2, DMAP1, CBX5, PYGO2, Figure 1—figure supplement 1A-D), TRIM28 is known to increase melanoma tumor propagation potential (Czerwinska et al., 2020).”</p></body></sub-article></article>